US20190216375A1 - Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device - Google Patents
Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device Download PDFInfo
- Publication number
- US20190216375A1 US20190216375A1 US16/360,295 US201916360295A US2019216375A1 US 20190216375 A1 US20190216375 A1 US 20190216375A1 US 201916360295 A US201916360295 A US 201916360295A US 2019216375 A1 US2019216375 A1 US 2019216375A1
- Authority
- US
- United States
- Prior art keywords
- medical device
- enclosure
- sleeve
- electronic medical
- opening
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 66
- 238000004140 cleaning Methods 0.000 title abstract description 54
- 230000000249 desinfective effect Effects 0.000 title abstract description 41
- 230000001681 protective effect Effects 0.000 claims description 59
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 33
- 239000008103 glucose Substances 0.000 claims description 33
- 239000000853 adhesive Substances 0.000 claims description 29
- 230000001070 adhesive effect Effects 0.000 claims description 29
- 239000000463 material Substances 0.000 claims description 26
- -1 polyethylene Polymers 0.000 claims description 14
- 229920000515 polycarbonate Polymers 0.000 claims description 6
- 239000004417 polycarbonate Substances 0.000 claims description 6
- 239000004698 Polyethylene Substances 0.000 claims description 5
- 238000004891 communication Methods 0.000 claims description 5
- 229920000573 polyethylene Polymers 0.000 claims description 5
- 229920002635 polyurethane Polymers 0.000 claims description 5
- 239000004814 polyurethane Substances 0.000 claims description 5
- 229920001684 low density polyethylene Polymers 0.000 claims description 4
- 239000004702 low-density polyethylene Substances 0.000 claims description 4
- 239000004676 acrylonitrile butadiene styrene Substances 0.000 claims description 3
- 238000003780 insertion Methods 0.000 claims description 3
- 230000037431 insertion Effects 0.000 claims description 3
- 238000012958 reprocessing Methods 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 2
- XECAHXYUAAWDEL-UHFFFAOYSA-N acrylonitrile butadiene styrene Chemical compound C=CC=C.C=CC#N.C=CC1=CC=CC=C1 XECAHXYUAAWDEL-UHFFFAOYSA-N 0.000 claims 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 claims 1
- 238000011109 contamination Methods 0.000 abstract description 6
- 230000005541 medical transmission Effects 0.000 abstract description 2
- 239000012491 analyte Substances 0.000 description 48
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 27
- 230000009467 reduction Effects 0.000 description 21
- 239000007788 liquid Substances 0.000 description 19
- 125000006850 spacer group Chemical group 0.000 description 17
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 14
- 239000007844 bleaching agent Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 239000011248 coating agent Substances 0.000 description 10
- 238000000576 coating method Methods 0.000 description 10
- 239000003599 detergent Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000004744 fabric Substances 0.000 description 9
- 238000000151 deposition Methods 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 210000004247 hand Anatomy 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 238000004659 sterilization and disinfection Methods 0.000 description 8
- 102000004877 Insulin Human genes 0.000 description 7
- 108090001061 Insulin Proteins 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940125396 insulin Drugs 0.000 description 7
- 238000012544 monitoring process Methods 0.000 description 7
- 230000008021 deposition Effects 0.000 description 6
- 239000000645 desinfectant Substances 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 230000035515 penetration Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000008399 tap water Substances 0.000 description 6
- 235000020679 tap water Nutrition 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000002745 absorbent Effects 0.000 description 5
- 239000002250 absorbent Substances 0.000 description 5
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 5
- 238000004590 computer program Methods 0.000 description 5
- 239000000356 contaminant Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000002791 soaking Methods 0.000 description 5
- CFFZDZCDUFSOFZ-UHFFFAOYSA-N 3,4-Dihydroxy-phenylacetic acid Chemical compound OC(=O)CC1=CC=C(O)C(O)=C1 CFFZDZCDUFSOFZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 3
- 241000725618 Duck hepatitis B virus Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 3
- 241000588747 Klebsiella pneumoniae Species 0.000 description 3
- 241000187495 Mycobacterium terrae Species 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 3
- HZCBWYNLGPIQRK-LBPRGKRZSA-N 3,3',5'-triiodo-L-thyronine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC=C1OC1=CC(I)=C(O)C(I)=C1 HZCBWYNLGPIQRK-LBPRGKRZSA-N 0.000 description 2
- WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 description 2
- DIVQKHQLANKJQO-UHFFFAOYSA-N 3-methoxytyramine Chemical compound COC1=CC(CCN)=CC=C1O DIVQKHQLANKJQO-UHFFFAOYSA-N 0.000 description 2
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 102000004452 Arginase Human genes 0.000 description 2
- 108700024123 Arginases Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 108010074051 C-Reactive Protein Proteins 0.000 description 2
- 102100032752 C-reactive protein Human genes 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 2
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 230000001680 brushing effect Effects 0.000 description 2
- 238000005229 chemical vapour deposition Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 229960002428 fentanyl Drugs 0.000 description 2
- PJMPHNIQZUBGLI-UHFFFAOYSA-N fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 2
- 210000003811 finger Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- RHCSKNNOAZULRK-UHFFFAOYSA-N mescaline Chemical compound COC1=CC(CCN)=CC(OC)=C1OC RHCSKNNOAZULRK-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229960000482 pethidine Drugs 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- 229950010883 phencyclidine Drugs 0.000 description 2
- PAHGJZDQXIOYTH-UHFFFAOYSA-N pristanic acid Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C(O)=O PAHGJZDQXIOYTH-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011253 protective coating Substances 0.000 description 2
- 238000005201 scrubbing Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000004544 sputter deposition Methods 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940034208 thyroxine Drugs 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- 238000007740 vapor deposition Methods 0.000 description 2
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- CIKNYWFPGZCHDL-ZHFUJENKSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[[(2s,3r)-3-amino-6-(aminomethyl)-3,4-dihydro-2h-pyran-2-yl]oxy]-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC=C(CN)O2)N)[C@@H](N)C[C@H]1N CIKNYWFPGZCHDL-ZHFUJENKSA-N 0.000 description 1
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- UUEZOEBHFHYMGR-RNWHKREASA-N (4r,4ar,7ar,12bs)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7-one;3-(4-chlorophenyl)-n,n-dimethyl-3-pyridin-2-ylpropan-1-amine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1.C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC UUEZOEBHFHYMGR-RNWHKREASA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- QNJJECIHYZJXRL-UHFFFAOYSA-N 1-(2-chlorophenyl)-2-methylpropan-2-amine;hydrochloride Chemical compound Cl.CC(C)(N)CC1=CC=CC=C1Cl QNJJECIHYZJXRL-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QNLDTXPVZPRSAM-UHFFFAOYSA-N 17146-95-1 Chemical compound CC(O)C(O)=O.C1C2=CC=C(O)C=C2C2(C)C(C)C1N(CC=C(C)C)CC2 QNLDTXPVZPRSAM-UHFFFAOYSA-N 0.000 description 1
- DBPWSSGDRRHUNT-UHFFFAOYSA-N 17alpha-hydroxy progesterone Natural products C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(=O)C)(O)C1(C)CC2 DBPWSSGDRRHUNT-UHFFFAOYSA-N 0.000 description 1
- UYVVLXVBEQAATF-WAIVXGPNSA-N 1b-Hydroxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)C[C@@H](O)[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 UYVVLXVBEQAATF-WAIVXGPNSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- PGTPSOVIAGCWHT-UHFFFAOYSA-N 2-(2-benzylphenoxy)-n,n-dimethylethanamine;n-(4-hydroxyphenyl)acetamide;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound CC(=O)NC1=CC=C(O)C=C1.OC(=O)CC(O)(C(O)=O)CC(O)=O.CN(C)CCOC1=CC=CC=C1CC1=CC=CC=C1 PGTPSOVIAGCWHT-UHFFFAOYSA-N 0.000 description 1
- PUAQLLVFLMYYJJ-UHFFFAOYSA-N 2-aminopropiophenone Chemical compound CC(N)C(=O)C1=CC=CC=C1 PUAQLLVFLMYYJJ-UHFFFAOYSA-N 0.000 description 1
- LCZBQMKVFQNSJR-UJPCIWJBSA-N 21-deoxycortisol Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)C[C@@H]2O LCZBQMKVFQNSJR-UJPCIWJBSA-N 0.000 description 1
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 description 1
- WYEPBHZLDUPIOD-UHFFFAOYSA-N 4,6-dioxoheptanoic acid Chemical compound CC(=O)CC(=O)CCC(O)=O WYEPBHZLDUPIOD-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- RVWZUOPFHTYIEO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Natural products C1=C(O)C=C2C(C(=O)O)=CNC2=C1 RVWZUOPFHTYIEO-UHFFFAOYSA-N 0.000 description 1
- 239000003310 5-hydroxyindoleacetic acid Substances 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N Acetoacetic acid Natural products CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 1
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 1
- 102100036664 Adenosine deaminase Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 1
- KZFBHCCLJSAHBQ-UHFFFAOYSA-N Benzoylecgonine Natural products CN1C2CCC1C(C(C2)OC(=C)c3ccccc3)C(=O)O KZFBHCCLJSAHBQ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010039206 Biotinidase Proteins 0.000 description 1
- 102100026044 Biotinidase Human genes 0.000 description 1
- JQJPBYFTQAANLE-UHFFFAOYSA-N Butyl nitrite Chemical compound CCCCON=O JQJPBYFTQAANLE-UHFFFAOYSA-N 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108010033547 Carbonic Anhydrase I Proteins 0.000 description 1
- 102100025518 Carbonic anhydrase 1 Human genes 0.000 description 1
- 108010075016 Ceruloplasmin Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- 235000001258 Cinchona calisaya Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 108010091326 Cryoglobulins Proteins 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 201000003808 Cystic echinococcosis Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 108010071840 Cytosol nonspecific dipeptidase Proteins 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical class OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- LHQIJBMDNUYRAM-AWFVSMACSA-N D-erythro-biopterin Chemical compound N1=C(N)NC(=O)C2=NC([C@H](O)[C@H](O)C)=CN=C21 LHQIJBMDNUYRAM-AWFVSMACSA-N 0.000 description 1
- FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 108010028196 Dihydropteridine Reductase Proteins 0.000 description 1
- 102100022317 Dihydropteridine reductase Human genes 0.000 description 1
- 241001319090 Dracunculus medinensis Species 0.000 description 1
- 241000244170 Echinococcus granulosus Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102100029115 Fumarylacetoacetase Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 108010007979 Glycocholic Acid Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 description 1
- 239000004866 Hashish Substances 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 208000032087 Hereditary Leber Optic Atrophy Diseases 0.000 description 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
- 102000016871 Hexosaminidase A Human genes 0.000 description 1
- 108010053317 Hexosaminidase A Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 108010056651 Hydroxymethylbilane synthase Proteins 0.000 description 1
- DOMWKUIIPQCAJU-LJHIYBGHSA-N Hydroxyprogesterone caproate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)CCCCC)[C@@]1(C)CC2 DOMWKUIIPQCAJU-LJHIYBGHSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 description 1
- 241000755266 Kathetostoma giganteum Species 0.000 description 1
- LHQIJBMDNUYRAM-UHFFFAOYSA-N L-erythro-Biopterin Natural products N1=C(N)NC(=O)C2=NC(C(O)C(O)C)=CN=C21 LHQIJBMDNUYRAM-UHFFFAOYSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 201000000639 Leber hereditary optic neuropathy Diseases 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 102000057248 Lipoprotein(a) Human genes 0.000 description 1
- 108010033266 Lipoprotein(a) Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000883511 Lophophora williamsii Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- JEYCTXHKTXCGPB-UHFFFAOYSA-N Methaqualone Chemical compound CC1=CC=CC=C1N1C(=O)C2=CC=CC=C2N=C1C JEYCTXHKTXCGPB-UHFFFAOYSA-N 0.000 description 1
- 229920001410 Microfiber Polymers 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- RFDAIACWWDREDC-UHFFFAOYSA-N Na salt-Glycocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)C(O)C2 RFDAIACWWDREDC-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000243985 Onchocerca volvulus Species 0.000 description 1
- 239000008896 Opium Substances 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 241000223810 Plasmodium vivax Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 229920001328 Polyvinylidene chloride Polymers 0.000 description 1
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- QVDSEJDULKLHCG-UHFFFAOYSA-N Psilocybine Natural products C1=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CNC2=C1 QVDSEJDULKLHCG-UHFFFAOYSA-N 0.000 description 1
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
- 238000001069 Raman spectroscopy Methods 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000606701 Rickettsia Species 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 1
- 241000242680 Schistosoma mansoni Species 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040860 Skin haemorrhages Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 102000002248 Thyroxine-Binding Globulin Human genes 0.000 description 1
- 108010000259 Thyroxine-Binding Globulin Proteins 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 241000223097 Trypanosoma rangeli Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 102100021436 UDP-glucose 4-epimerase Human genes 0.000 description 1
- 108010075202 UDP-glucose 4-epimerase Proteins 0.000 description 1
- 108010058532 UTP-hexose-1-phosphate uridylyltransferase Proteins 0.000 description 1
- 102000006321 UTP-hexose-1-phosphate uridylyltransferase Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 241000244005 Wuchereria bancrofti Species 0.000 description 1
- 102100039662 Xaa-Pro dipeptidase Human genes 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 108010063628 acarboxyprothrombin Proteins 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229960003116 amyl nitrite Drugs 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000003460 anti-nuclear Effects 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000001505 atmospheric-pressure chemical vapour deposition Methods 0.000 description 1
- 238000000277 atomic layer chemical vapour deposition Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- ANFSNXAXVLRZCG-RSAXXLAASA-N benzphetamine hydrochloride Chemical compound [Cl-].C([C@H](C)[NH+](C)CC=1C=CC=CC=1)C1=CC=CC=C1 ANFSNXAXVLRZCG-RSAXXLAASA-N 0.000 description 1
- 208000005980 beta thalassemia Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 244000078885 bloodborne pathogen Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 239000012459 cleaning agent Substances 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- CZWCKYRVOZZJNM-USOAJAOKSA-N dehydroepiandrosterone sulfate Chemical compound C1[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 CZWCKYRVOZZJNM-USOAJAOKSA-N 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 239000000747 designer drug Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- QMQBBUPJKANITL-MYXGOWFTSA-N dextropropoxyphene hydrochloride Chemical compound [H+].[Cl-].C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 QMQBBUPJKANITL-MYXGOWFTSA-N 0.000 description 1
- WOWBFOBYOAGEEA-UHFFFAOYSA-N diafenthiuron Chemical compound CC(C)C1=C(NC(=S)NC(C)(C)C)C(C(C)C)=CC(OC=2C=CC=CC=2)=C1 WOWBFOBYOAGEEA-UHFFFAOYSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229960002069 diamorphine Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229940120144 didrex Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- HYPPXZBJBPSRLK-UHFFFAOYSA-N diphenoxylate Chemical compound C1CC(C(=O)OCC)(C=2C=CC=CC=2)CCN1CCC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 HYPPXZBJBPSRLK-UHFFFAOYSA-N 0.000 description 1
- QCHSEDTUUKDTIG-UHFFFAOYSA-L dipotassium clorazepate Chemical compound [OH-].[K+].[K+].C12=CC(Cl)=CC=C2NC(=O)C(C(=O)[O-])N=C1C1=CC=CC=C1 QCHSEDTUUKDTIG-UHFFFAOYSA-L 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- GVGYEFKIHJTNQZ-RFQIPJPRSA-N ecgonine benzoate Chemical compound O([C@@H]1[C@@H]([C@H]2CC[C@@H](C1)N2C)C(O)=O)C(=O)C1=CC=CC=C1 GVGYEFKIHJTNQZ-RFQIPJPRSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 238000010894 electron beam technology Methods 0.000 description 1
- 238000004924 electrostatic deposition Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 108010022687 fumarylacetoacetase Proteins 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 230000010030 glucose lowering effect Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- RFDAIACWWDREDC-FRVQLJSFSA-N glycocholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 RFDAIACWWDREDC-FRVQLJSFSA-N 0.000 description 1
- 229940099347 glycocholic acid Drugs 0.000 description 1
- 239000000380 hallucinogen Substances 0.000 description 1
- 229960003242 halofantrine Drugs 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 208000034737 hemoglobinopathy Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000004050 hot filament vapor deposition Methods 0.000 description 1
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- JUMYIBMBTDDLNG-OJERSXHUSA-N hydron;methyl (2r)-2-phenyl-2-[(2r)-piperidin-2-yl]acetate;chloride Chemical compound Cl.C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 JUMYIBMBTDDLNG-OJERSXHUSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229950000801 hydroxyprogesterone caproate Drugs 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000018337 inherited hemoglobinopathy Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940087973 lomotil Drugs 0.000 description 1
- 238000004518 low pressure chemical vapour deposition Methods 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 240000004308 marijuana Species 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229960001962 mefloquine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960002803 methaqualone Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003658 microfiber Substances 0.000 description 1
- 238000000259 microwave plasma-assisted chemical vapour deposition Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000001451 molecular beam epitaxy Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- FYHCHSNOXWVJJT-UHFFFAOYSA-N n-debutylhalofantrine Chemical compound FC(F)(F)C1=CC=C2C(C(O)CCNCCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FYHCHSNOXWVJJT-UHFFFAOYSA-N 0.000 description 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229960001027 opium Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007649 pad printing Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 229940011043 percocet Drugs 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- OOBHFESNSZDWIU-UHFFFAOYSA-N phenmetrazine Chemical compound CC1NCCOC1C1=CC=CC=C1 OOBHFESNSZDWIU-UHFFFAOYSA-N 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 238000005240 physical vapour deposition Methods 0.000 description 1
- 238000000623 plasma-assisted chemical vapour deposition Methods 0.000 description 1
- 229920001084 poly(chloroprene) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000005033 polyvinylidene chloride Substances 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229950009829 prasterone sulfate Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 108010066823 proline dipeptidase Proteins 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- QKTAAWLCLHMUTJ-UHFFFAOYSA-N psilocybin Chemical compound C1C=CC(OP(O)(O)=O)=C2C(CCN(C)C)=CN=C21 QKTAAWLCLHMUTJ-UHFFFAOYSA-N 0.000 description 1
- 238000004549 pulsed laser deposition Methods 0.000 description 1
- 229960000948 quinine Drugs 0.000 description 1
- 238000001289 rapid thermal chemical vapour deposition Methods 0.000 description 1
- 238000005546 reactive sputtering Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000000663 remote plasma-enhanced chemical vapour deposition Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 239000012858 resilient material Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 229940099204 ritalin Drugs 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 108010093322 s-formylglutathione hydrolase Proteins 0.000 description 1
- 102000028528 s-formylglutathione hydrolase Human genes 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 206010039766 scrub typhus Diseases 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 235000019832 sodium triphosphate Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 238000004528 spin coating Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 229960004673 sulfadoxine Drugs 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229940066690 talwin Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960005367 tetanus antitoxin Drugs 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 238000002207 thermal evaporation Methods 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- LOIYMIARKYCTBW-OWOJBTEDSA-N trans-urocanic acid Chemical compound OC(=O)\C=C\C1=CNC=N1 LOIYMIARKYCTBW-OWOJBTEDSA-N 0.000 description 1
- LOIYMIARKYCTBW-UHFFFAOYSA-N trans-urocanic acid Natural products OC(=O)C=CC1=CNC=N1 LOIYMIARKYCTBW-UHFFFAOYSA-N 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 229940063648 tranxene Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229940035722 triiodothyronine Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229940071950 tussionex Drugs 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000000038 ultrahigh vacuum chemical vapour deposition Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229940072690 valium Drugs 0.000 description 1
- 238000005019 vapor deposition process Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- FUTVBRXUIKZACV-UHFFFAOYSA-J zinc;3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate Chemical compound [Zn+2].[N-]1C2=C(C)C(CCC([O-])=O)=C1C=C([N-]1)C(CCC([O-])=O)=C(C)C1=CC(C(C)=C1C=C)=NC1=CC(C(C)=C1C=C)=NC1=C2 FUTVBRXUIKZACV-UHFFFAOYSA-J 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45C—PURSES; LUGGAGE; HAND CARRIED BAGS
- A45C11/00—Receptacles for purposes not provided for in groups A45C1/00-A45C9/00
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45C—PURSES; LUGGAGE; HAND CARRIED BAGS
- A45C11/00—Receptacles for purposes not provided for in groups A45C1/00-A45C9/00
- A45C11/003—Receptacles for purposes not provided for in groups A45C1/00-A45C9/00 for storing portable computing devices, e.g. laptops, tablets or calculators
-
- A45C2011/003—
-
- A—HUMAN NECESSITIES
- A45—HAND OR TRAVELLING ARTICLES
- A45C—PURSES; LUGGAGE; HAND CARRIED BAGS
- A45C11/00—Receptacles for purposes not provided for in groups A45C1/00-A45C9/00
- A45C2011/007—Receptacles for personal medical or care products, e.g. drugs, condoms or patches; Small first-aid kits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/24—Hygienic packaging for medical sensors; Maintaining apparatus for sensor hygiene
- A61B2562/245—Means for cleaning the sensor in-situ or during use, e.g. hygienic wipes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2562/00—Details of sensors; Constructional details of sensor housings or probes; Accessories for sensors
- A61B2562/24—Hygienic packaging for medical sensors; Maintaining apparatus for sensor hygiene
- A61B2562/247—Hygienic covers, i.e. for covering the sensor or apparatus during use
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T29/00—Metal working
- Y10T29/49—Method of mechanical manufacture
- Y10T29/49826—Assembling or joining
Definitions
- the present invention relates to medical devices, and, more particularly to maintaining cleanliness in such devices and to cleaning such devices.
- Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (Type 2 or non-insulin dependent).
- Type I or insulin dependent in which the pancreas cannot create sufficient insulin
- Type 2 or non-insulin dependent in which insulin is not effective
- a hypoglycemic reaction low blood sugar
- a person with diabetes carries a self-monitoring blood glucose (SMBG) monitor, which typically requires uncomfortable finger pricking methods. Due to the lack of comfort and convenience, a person with diabetes normally only measures his or her glucose levels two to four times per day. Unfortunately, such time intervals are so far spread apart that the person with diabetes likely finds out too late of a hyperglycemic or hypoglycemic condition, sometimes incurring dangerous side effects.
- Glucose levels may be alternatively monitored continuously by a sensor system including an on-skin sensor assembly.
- the sensor system may have a wireless transmitter that transmits measurement data to a receiver that processes and displays information based on the measurements.
- Such sensor systems are sometimes referred to as continuous glucose monitors (CGMs).
- certain components of a CGM may be used by more than one person.
- diabetes patients may wish to try a CGM for a limited time on a trial basis, such as when a patient tests a CGM for the first time before committing to using one on a more permanent basis, or when a patient who currently uses a CGM wishes to try a new model, brand, etc.
- certain of the present embodiments comprise an enclosure for an electronic medical device.
- the enclosure comprises a sleeve configured to receive an electronic medical device having a port.
- the enclosure further comprises a first opening in the sleeve sized and configured to allow for insertion of the electronic medical device into the sleeve and removal of the electronic medical device from the sleeve.
- the enclosure further comprises a second opening in the sleeve, the second opening being located so as to permit access to the port when the electronic medical device is received within the sleeve.
- the enclosure further comprises a first cover configured to adhere to a first portion of the sleeve and to cover the first opening.
- the enclosure further comprises a second cover configured to adhere to a second portion of the sleeve and to cover the second opening.
- the enclosure further comprises a first adhesive located and configured to secure the first cover to the sleeve at the first portion.
- the enclosure further comprises a second adhesive located and configured to secure the second cover to the sleeve at the second portion.
- the first adhesive comprises a first peel strength
- the second adhesive comprises a second peel strength
- the first peel strength is different than the second peel strength
- the first peel strength is greater than the second peel strength.
- the first peel strength is great enough to prevent separation of the first cover from the sleeve without tearing the sleeve.
- the port is at least one of a charging port or a communication port.
- the communication port is a USB port.
- the sleeve comprises a material selected from the group consisting of: polyurethane, polyethylene, and low density polyethylene.
- the sleeve comprises a first portion comprising a first material and a second portion comprising a second material.
- the second material has greater stiffness than the first material.
- the first portion comprises a material selected from the group consisting of: polyurethane, polyethylene, and low density polyethylene.
- the second portion comprises a material selected from the group consisting of: polycarbonate and acrylonitrile butadiene styrene (ABS).
- ABS acrylonitrile butadiene styrene
- the second portion is configured to provide access to the port.
- the first opening is surrounded by the first portion, and wherein the second opening is surrounded by the second portion.
- the first opening comprises a first slit that extends in a longitudinal direction, and a second slit that extends in a transverse direction.
- a first end of the first slit corresponds to a lengthwise center of the second slit.
- the electronic medical device is configured to display continuous glucose concentration data over a time period.
- certain of the present embodiments comprise a method for reprocessing a reusable electronic medical device.
- the method comprises receiving an electronic medical device from a first user, wherein the electronic medical device is contained in a first protective enclosure.
- the method further comprises removing the electronic medical device from the first protective enclosure.
- the method further comprises inserting the electronic medical device into a second protective enclosure through an opening in the second protective enclosure.
- the method further comprises adhering a cover to the second protective enclosure over the opening such that the cover cannot be separated from the second protective enclosure without damaging the second protective enclosure.
- the method further comprises providing the electronic medical device contained within the second protective enclosure to a second user.
- the method further comprises creating a disinfected field, wherein removing the electronic medical device from the first protective enclosure and placing the electronic medical device in a second protective enclosure are performed in the disinfected field.
- removing the electronic medical device from the first protective enclosure requires tearing the first protective enclosure.
- the method further comprises cleaning and disinfecting the electronic medical device.
- the electronic medical device is configured to display continuous glucose concentration data over a time period.
- certain of the present embodiments comprise a case for protecting an electronic medical device.
- the case comprises a housing defining a cavity configured to receive an electronic medical device having a port.
- the housing comprises an opening located and configured to allow access to the port when the electronic medical device is contained within the housing.
- the housing further comprises a lock, which, when in a locked position, is configured to prevent opening of the housing to thereby selectively deter removal of the electronic medical device from the housing.
- unlocking the lock enables removal of the electronic medical device from the housing.
- An embodiment of the third aspect comprises the case in combination with a key configured to lock and unlock the lock.
- the housing comprises a first portion and a second portion, and when the first and second portions engage one another and the lock is in the locked position, the first and second portions cannot be separated from one another without damaging at least one of the first and second portions.
- the housing when in a closed and locked configuration, meets the IPX7 standard with respect to water penetration.
- the housing comprises a material selected from the group consisting of: polycarbonate and acrylonitrile butadiene styrene (ABS).
- ABS acrylonitrile butadiene styrene
- the electronic medical device comprises electronics and a display.
- the electronic medical device is configured to display continuous glucose concentration data over a time period.
- certain of the present embodiments comprise a case for protecting an electronic medical device.
- the case comprises a housing defining a cavity configured to receive an electronic medical device having a port.
- the housing comprises a first portion, a second portion, and an opening located and configured to allow access to the port when the electronic medical device is contained within the housing.
- the housing further comprises at least one fastener configured to secure the first and second portions to one another and prevent access to the cavity to thereby selectively deter removal of the electronic medical device from the housing. The fastener, when in a secured position, cannot be removed from the first and second portions by hand.
- certain of the present embodiments comprise a method for reprocessing a reusable electronic medical device.
- the method comprises receiving an electronic medical device from a first user, the electronic medical device including a water resistant protective coating.
- the method further comprises cleaning the electronic medical device to achieve a concentration in protein on surfaces of the electronic medical device of less than about 6.4 ⁇ g/cm 2 , and a concentration in hemoglobin on surfaces of the electronic medical device of less than about 2.2 ⁇ g/cm 2 .
- the method further comprises disinfecting the electronic medical device to achieve reductions in duck hepatitis B virus of at least about a 3 log 10 reduction, in klebsiella pneumonia of least about a 6 log 10 reduction, in staphylococcus aureus of least about a 6 log 10 reduction, in escherichia coli of least about a 6 log 10 reduction, in pseudomonas aeruginosa of least about a 6 log 10 reduction, and in mycobacterium terrae of least about a 3 log 10 reduction.
- At least one of cleaning the electronic medical device or disinfecting the electronic medical device comprises submerging the electronic medical device in a cleaning solution and/or a disinfecting solution.
- the method further comprises providing the cleaned and disinfected electronic medical device to a second user.
- the water resistant protective coating protects the electronic medical device from damage from liquid ingress.
- the method further comprises drying the electronic medical device.
- the electronic medical device includes at least electronics, a port, a display, and a speaker.
- the electronic medical device is configured to display continuous glucose concentration data over a time period.
- certain of the present embodiments comprise a method for cleaning and disinfecting an electronic medical device.
- the method comprises cleaning the electronic medical device to achieve a concentration in protein on surfaces of the electronic medical device of less than about 6.4 ⁇ g/cm 2 , and a concentration in hemoglobin on surfaces of the electronic medical device of less than about 2.2 ⁇ g/cm 2 .
- the method further comprises disinfecting the electronic medical device to achieve reductions in duck hepatitis B virus of at least about 3 a log 10 reduction, in klebsiella pneumonia of at least about a 6 log 10 reduction, in staphylococcus aureus of at least about a 6 log 10 reduction, in escherichia coli of at least about a 6 log 10 reduction, in pseudomonas aeruginosa of at least about a 6 log 10 reduction, and in mycobacterium terrae of at least about a 3 log 10 reduction.
- the method further comprises drying the electronic medical device.
- the electronic medical device comprises at least electronics, a port, a display, and a speaker.
- the electronic medical device is configured to display continuous glucose concentration data over a time period.
- kits for covering and protecting an electronic medical device comprising a sleeve configured to receive an electronic medical device having a port.
- the sleeve comprises a first opening sized and configured to allow for insertion of the electronic medical device into the sleeve and removal of the electronic medical device from the sleeve.
- the sleeve further comprises a second opening in the sleeve, the second opening being located so as to permit access to the port when the electronic medical device is received within the sleeve.
- the kit further comprises a first closure configured to adhere to a first portion of the sleeve and to overlie and seal the first opening.
- the kit further comprises a second closure configured to adhere to a second portion of the sleeve and to overlie and seal the second opening.
- the kit further comprises an acoustic spacer configured to be interposed between the sleeve and the electronic medical device to create a space between the sleeve and the electronic medical device.
- each of the first and second closures includes an adhesive backing.
- the electronic medical device is configured to display continuous glucose concentration data over a time period.
- FIG. 1 is a schematic view of a continuous analyte sensor system attached to a host and communicating with other devices;
- FIG. 2 is a rear perspective view of one embodiment of a protective sleeve for receiving a medical device
- FIG. 3A is a front perspective view of the protective sleeve of FIG. 2 with a medical device received therein;
- FIG. 3B is a front perspective view of the protective sleeve and the medical device of FIG. 3A in combination with acoustic spacers;
- FIG. 4A is a rear perspective view of the protective sleeve of FIG. 2 ;
- FIG. 4B is a rear perspective view of another embodiment of a protective sleeve for receiving a medical device
- FIG. 4C is perspective view of a kit including the protective sleeve of FIG. 4B , one of the acoustic spacers of FIG. 3B , and closures configured for use with the sleeve of FIG. 4B ;
- FIG. 4D is a rear perspective view of the sleeve of FIG. 4B and the closures of FIG. 4C ;
- FIG. 5 is a front perspective view of one embodiment of a case for receiving a medical device:
- FIG. 6 is a front perspective view of a other embodiment of a case for receiving a medical device.
- FIGS. 7 and 8 are flowcharts illustrating embodiments of methods for cleaning a medical device
- FIGS. 9 and 10 are flowcharts illustrating embodiments of methods for disinfecting a medical device
- FIG. 11 is a flowchart illustrating another embodiment of a method for cleaning a medical device.
- FIG. 12 is a flowchart illustrating another embodiment of a method for disinfecting a medical device.
- the preferred embodiments relate to the use of an analyte sensor that measures a concentration of glucose or a substance indicative of the concentration or presence of the analyte.
- the analyte sensor is a continuous device, for example a subcutaneous, transdermal, transcutaneous, and/or intravascular (e.g., intravenous) device.
- the device can analyze a plurality of intermittent blood samples.
- the analyte sensor can use any method of glucose-measurement, including enzymatic, chemical, physical, electrochemical, optical, optochemical, fluorescence-based, spectrophotometric, spectroscopic (e.g., optical absorption spectroscopy, Raman spectroscopy, etc.), polarimetric, calorimetric, iontophoretic, radiometric, and the like.
- the analyte sensor can use any known method, including invasive, minimally invasive, and non-invasive sensing techniques, to provide a data stream indicative of the concentration of the analyte in a host.
- the data stream is typically a raw data signal that is used to provide a useful value of the analyte to a user, such as a patient or health care professional (e.g., doctor), who may be using the sensor.
- the systems and methods of the preferred embodiments can be applied to any measurable analyte.
- the analyte sensor is a glucose sensor capable of measuring the concentration of glucose in a host.
- One example embodiment is described below, which utilizes an implantable glucose sensor.
- the devices and methods described herein can be applied to any device capable of detecting a concentration of analyte and providing an output signal that represents the concentration of the analyte.
- the analyte sensor is an implantable glucose sensor, such as described with reference to U.S. Pat. No. 6,001,067 and U.S. Patent Publication No. US-2011-0027127-A1.
- the analyte sensor is a transcutaneous glucose sensor, such as described with reference to U.S. Patent Publication No. US-2006-0020187-A1.
- the analyte sensor is a dual electrode analyte sensor, such as described with reference to U.S. Patent Publication No. US-2009-0137887-A1.
- the sensor is configured to be implanted in a host vessel or extracorporeally, such as is described in U.S. Patent Publication No. US-2007-0027385-A1.
- the membrane system can be deposited on the exposed electroactive surfaces using any variety of known thin film techniques (for example, vapor deposition, spraying, printing (e.g., pad printing), electro-depositing, dipping, sputtering deposition, spin coating, powder coating, and the like).
- vapor deposition for example, vapor deposition, spraying, printing (e.g., pad printing), electro-depositing, dipping, sputtering deposition, spin coating, powder coating, and the like.
- vapor deposition processes e.g., physical and/or chemical vapor deposition processes
- other vapor deposition processes can be useful for providing one or more of the insulating and/or membrane layers, including ultrasonic vapor deposition, electrostatic deposition, evaporative deposition, deposition by sputtering, pulsed laser deposition, high velocity oxygen fuel deposition, thermal evaporator deposition, electron beam evaporator deposition, deposition by reactive sputtering molecular beam epitaxy, atmospheric pressure chemical vapor deposition (CVD), atomic layer CVD, hot wire CVD, low-pressure CVD, microwave plasma-assisted CVD, plasma-enhanced CVD, rapid thermal CVD, remote plasma-enhanced CVD, and ultra-high vacuum CVD, for example.
- the membrane system can be disposed over (or deposited on) the electroactive surfaces using any known method, as will be appreciated by one skilled in the art.
- analyte as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and it is not to be limited to a special or customized meaning), and refers without limitation to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine) that can be analyzed. Analytes may include naturally occurring substances, artificial substances, metabolites, and/or reaction products. In some embodiments, the analyte for measurement by the sensor heads, devices, and methods disclosed herein is glucose.
- analytes include but not limited to lactate or lactic acid; cardiac markers; ketone bodies; acetone; acetoacetic acid; beta hydroxybutyric acid; glucagon, acetyl Co A; intermediaries in the Citric Acid Cycle; choline, testosterone; creatinine; triglycerides; sodium; potassium; chloride; bicarbonate; total protein; alkaline phosphatase; calcium; phosphorus; PO 2 ; PCO 2 ; bilirubin (direct and total); red blood cell count; white blood cell count; hemoglobin; hemactocrit; lymphocytes; monocytes; eosinophils; basophils; c-reactive protein; cryoglobulins; fibrinogens; ACTH; aldosterone; ammonia; beta-HCG; magnesium; copper; iron; total cholesterol; low density lipoproteins; high density lipoproteins; lipoprotein A; T4 (total and free); TSH
- Salts, sugar, protein, fat, vitamins, and hormones naturally occurring in blood or interstitial fluids may also constitute analytes in certain embodiments.
- the analyte may be naturally present in the biological fluid, for example, a metabolic product, a hormone, an antigen, an antibody, and the like.
- the analyte may be introduced into the body, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, p
- Analytes such as neurochemicals and other chemicals generated within the body may also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5HT), and 5-hydroxyindoleacetic acid (FHIAA).
- ascorbic acid such ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5HT), and 5-hydroxyindoleacetic acid (FHIAA).
- an analyte monitoring system 100 includes a continuous analyte sensor system 8 .
- Continuous analyte sensor system 8 includes a sensor electronics module 12 and a continuous analyte sensor 10 .
- the system 100 can also include other devices and/or sensors, such as a medicament delivery pump 2 and a reference analyte meter 4 , as illustrated in FIG. 1 .
- the continuous analyte sensor 10 may be physically connected to sensor electronics module 12 and may be integral with (e.g., non-releasably attached to) or releasably attachable to the continuous analyte sensor 10 .
- the continuous analyte sensor 10 may be physically separate to sensor electronics module 12 , but electronically coupled via inductive coupling or the like.
- the sensor electronics module 12 , medicament delivery pump 2 , and/or analyte reference meter 4 may communicate with one or more additional devices, such as any or all of display devices 14 , 16 , 18 , 20 , and 21 .
- the system 100 of FIG. 1 also includes a cloud-based processor 22 configured to analyze analyte data, medicament delivery data, and/or other patient related data provided over network 24 directly or indirectly from one or more of sensor system 8 , medicament delivery pump 2 , reference analyte meter 4 , and display devices 14 - 21 . Based on the received data, the processor 22 can further process the data, generate reports providing statistic based on the processed data, trigger notifications to electronic devices associated with the host or caretaker of the host, or provide processed information to any of the other devices of FIG. 1 .
- the cloud-based processor 22 comprises one or more servers. If the cloud-based processor 22 comprises multiple servers, the servers can be either geographically local or separate from one another.
- the network 24 can include any wired and wireless communication medium to transmit data, including WiFi networks, cellular networks, the Internet and any combinations thereof.
- FIG. 1 refers to analyte data being received by processor 22
- other types of data processed and raw data may be received as well.
- the sensor electronics module 12 may include electronic circuitry associated with measuring and processing data generated by the continuous analyte sensor 10 .
- This generated continuous analyte sensor data may also include algorithms, which can be used to process and calibrate the continuous analyte sensor data, although these algorithms may be provided in other ways as well.
- the sensor electronics module 12 may include hardware, firmware, software, or a combination thereof to provide measurement of levels of the analyte via a continuous analyte sensor, such as a continuous glucose sensor.
- the sensor electronics module 12 may, as noted, couple (e.g., wirelessly and the like) with one or more devices, such as any or all of display devices 14 , 16 , 18 , 20 , and 21 .
- the display devices 14 , 16 , 18 , 20 , and/or 21 may be configured for processing and presenting information, such sensor information transmitted by the sensor electronics module 12 for display at the display device.
- the display devices 14 , 16 , 18 , 20 , and 21 can also trigger alarms based on the analyte sensor data.
- display device 14 is a key fob-like display device
- display device 16 is a hand-held application-specific computing device 16 (e.g. the DexCom G4® Platinum receiver commercially available from DexCom, Inc.)
- display device 18 is a general purpose smart phone or tablet computing device 20 (e.g. an Apple® iPhone®, iPad®, or iPod Touch® commercially available from Apple, Inc.)
- display device 20 is a computer workstation 20
- display device 21 is any wearable.
- the relatively small, key fob-like display device 14 may be a computing device embodied in a wrist watch, a belt, a necklace, a pendent, a piece of jewelry, an adhesive patch, a pager, a key fob, a plastic card (e.g., credit card), an identification (ID) card, and/or the like.
- This small display device 14 may include a relatively small display (e.g., smaller than the display device 18 ) and may be configured to display a limited set of displayable sensor information, such as a numerical value 26 and/or an arrow 28 .
- display devices 16 , 18 , and 20 can be larger display devices that can be capable of displaying a larger set of displayable information, such as a trend graph 30 depicted on the hand-held receiver 16 in addition to other information such as a numerical value and arrow.
- any other user equipment e.g. computing devices
- a medicament delivery information e.g., discrete self-monitoring analyte readings, heart rate monitor, caloric intake monitor, and the like
- a medicament delivery information e.g., a medicament delivery information, discrete self-monitoring analyte readings, heart rate monitor, caloric intake monitor, and the like
- the continuous analyte sensor 10 comprises a sensor for detecting and/or measuring analytes, and the continuous analyte sensor 10 may be configured to continuously detect and/or measure analytes as a non-invasive device, a subcutaneous device, a transdermal device, and/or an intravascular device. In some example implementations, the continuous analyte sensor 10 may analyze a plurality of intermittent blood samples, although other analytes may be used as well.
- the continuous analyte sensor 10 may comprise a glucose sensor configured to measure glucose in the blood using one or more measurement techniques, such as enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, iontophoretic, radiometric, immunochemical, and the like.
- the glucose sensor may be comprise any device capable of measuring the concentration of glucose and may use a variety of techniques to measure glucose including invasive, minimally invasive, and non-invasive sensing techniques (e.g., fluorescent monitoring), to provide a data, such as a data stream, indicative of the concentration of glucose in a host.
- the data stream may be raw data signal, which is converted into a calibrated and/or filtered data stream used to provide a value of glucose to a host, such as a user, a patient, or a caretaker (e.g., a parent, a relative, a guardian, a teacher, a doctor, a nurse, or any other individual that has an interest in the wellbeing of the host).
- a host such as a user, a patient, or a caretaker (e.g., a parent, a relative, a guardian, a teacher, a doctor, a nurse, or any other individual that has an interest in the wellbeing of the host).
- the continuous analyte sensor 10 may be implanted as at least one of the following types of sensors: an implantable glucose sensor, a transcutaneous glucose sensor, implanted in a host vessel or extracorporeally, a subcutaneous sensor, a refillable subcutaneous sensor, an intravascular sensor.
- the continuous analyte sensor system 8 includes a DexCom G4® Platinum glucose sensor and transmitter commercially available from DexCom, Inc., for continuously monitoring a host's glucose levels.
- medical devices may in some cases be used by more than one patient.
- the medical device receiver 16 of FIG. 1 may be used by multiple patients on a trial basis so that each patient can determine whether a particular model of receiver is the right one for him or her before committing to buying one.
- the present embodiments described in detail below, provide various apparatus and methods for maintaining a medical device in a cleaned and disinfected state, and for cleaning and disinfecting a medical device after use.
- FIGS. 2-4A illustrate one embodiment of a protective sleeve 200 for receiving an electronic medical device 201 ( FIG. 3A ) to reduce the risk of contamination of the medical device 201 .
- the sleeve 200 preferably resists penetration of contaminants into an interior of the sleeve 200 so that such contaminants cannot reach the medical device 201 contained within the sleeve 200 .
- the sleeve 200 may be designed for a single use, after which the sleeve 200 may be disposed of. In other embodiments, the sleeve 200 may be designed for multiple uses, which may comprise cleaning and disinfecting between uses.
- the sleeve 200 comprises a body portion 202 defining an internal space 204 for receiving the medical device 201 .
- the body portion 202 is sized and shaped such that it can be formed to have a shape such that the space 204 is substantially the same size and shape as the medical device 201 , so that the sleeve 200 fits over the medical device 201 in a closely conforming fashion, as shown in FIGS. 3A and 3B .
- the body portion 202 may also be sized so that the space 204 is slightly smaller than the medical device 201 , so that the sleeve 200 stretches in order to fit over the medical device 201 in a closely conforming fashion.
- the sleeve 200 is shaped substantially as a rectangular parallelepiped when expanded, but in other embodiments the sleeve can be designed to have any shape to fit any of a variety of medical devices.
- a back panel 206 of the sleeve 200 includes an ingress/egress opening 208 through which the medical device 201 may be passed to insert the medical device 201 into the sleeve 200 and to withdraw the medical device 201 from the sleeve 200 .
- the opening 208 comprises a first slit 210 in the back panel 206 that runs substantially parallel to a longitudinal axis of the sleeve 200 , and a second slit 212 in the back panel 206 that runs substantially perpendicular to the longitudinal axis of the sleeve 200 , and which intersects a first end 214 of the first slit 210 .
- the opening 208 is thus substantially T-shaped.
- the opening 208 can have any of a variety of configurations.
- an end panel 216 of the sleeve 200 includes an access opening 218 through which one or more ports of the medical device 201 may be accessed.
- the medical device 201 may include a Universal Serial Bus (USB) port 220 ( FIG. 3A ) to enable the medical device 201 to communicate with a computing system through a wired connection, and/or a jack (not shown) for receiving a plug of a charging cord or adapter (not shown).
- USB Universal Serial Bus
- the access opening 218 thus enables the medical device 201 to be charged and/or connected to a computing system without the need to remove the sleeve 200 .
- the sleeve 200 is preferably constructed of a durable material (e.g., an elastic polymer) that can stretch and conform to the contours of the medical device 201 .
- the sleeve 200 may be formed of a rigid or semi-rigid material.
- the sleeve may comprise one or more portions that comprise a rigid or semi-rigid material and one or more other portions that comprise an elastic material.
- the sleeve 200 may be transparent or translucent, while in other embodiments the sleeve 200 may be opaque.
- the sleeve 200 may comprise any of a variety of materials, including, but not limited to, polyurethane, polypropylene, polyethylene, polyethylene terephthalate, polyvinyl chloride, polyvinylidene chloride, polystyrene, polyamide, polycarbonate, silicone, neoprene, and copolymers or combinations thereof.
- the material of the sleeve 200 is preferably resistant to common cleaning and disinfecting solutions, such as, for example, water, an enzyme active powdered detergent that is a concentrated anionic detergent, such as TERGAZYME®, bleach (e.g. up to 50% concentration), isopropyl alcohol (ISA), Pine Quat 64 Disinfectant (e.g.
- the back panel 206 of the sleeve 200 comprises a first closure 222 adjacent the ingress/egress opening 208 and a second closure 224 adjacent the access opening 218 .
- Each of the illustrated closures 222 , 224 is substantially rectangular, but in other embodiments they could be any shape.
- the first closure 222 is configured to selectively cover the ingress/egress opening 208
- the second closure 224 is configured to selectively cover the access opening 218 , as described below.
- the first closure 222 comprises a separate piece that is secured to the back panel 206 along a first edge 226
- the second closure 224 comprises a separate piece that is secured to the end panel 216 along a first edge 228
- either or both of the closures 222 , 224 may be integrally formed with the body 202 .
- Dimensions of each closure 222 , 224 are sufficient to enable each closure 222 , 224 to completely cover its respective opening 208 , 218 .
- Adhesive(s) may be applied to either or both of the first and second closures 222 , 224 and/or to either or both of the back panel 206 and the end panel 216 .
- the adhesive(s) enable the closures 222 , 224 to be secured to their respective panels 206 , 216 while covering their respective openings 208 , 218 .
- a first adhesive 230 is applied to the first closure 222 and/or to the back panel 206
- a second adhesive 232 is applied to the second closure 224 , and/or to the end panel 216 , and/or to the back panel 206 adjacent the access opening 218
- the first and second adhesives 230 , 232 have different adhesion strengths.
- the first adhesive 230 may have greater adhesion strength than the second adhesive 232 .
- the second closure 224 may be repeatedly adhered to and peeled from the back/end panel(s) 206 , 216 so that any ports covered by the second closure 224 can be repeatedly accessed and the access opening 218 subsequently resealed.
- each of the closures 222 , 224 comprises an adhesive on the side that is to be adhered to the sleeve 200 .
- a disposable peel-away backing paper may cover the adhesive backing on each of the closures 222 , 224 to prevent the closures 222 , 224 from adhering to any surfaces prior to being secured to the sleeve 200 , and to prevent the adhesive backings from attracting and adhering any debris prior to being secured to the sleeve 200 .
- the protective sleeve 200 described above allows the medical device 201 to be used for multiple patients, with a new protective sleeve 200 applied to the medical device 201 for each patient.
- the protective sleeve 200 is disposable and is intended for single-patient use. Using a new protective sleeve 200 for each patient helps prevent cross-contamination from patient to patient.
- the protective sleeve 200 also protects the medical device 201 from contamination and liquid ingress.
- FIG. 3B illustrates the protective sleeve 200 and the medical device 201 in combination with acoustic spacers 203 .
- the medical device 201 includes a pair of speakers 205 located at opposite corners 207 of one end of the medical device 201 .
- the speakers 205 are configured to emit audible tones, such as tones to alert the patient to various conditions.
- the protective sleeve 200 overlies the speakers 205 .
- the acoustic spacers 203 may be interposed between the medical device 201 and the protective sleeve 200 at the corners 207 , as further discussed below.
- Each acoustic spacer 203 includes first and second segments 209 , 211 that extend in perpendicular directions from a junction 213 .
- Each acoustic spacer 203 is oriented such that the junction 213 aligns with its respective corner 207 of the medical device 201 , with the first and second segments 209 , 211 extending along perpendicular sides of the medical device 201 , as shown in FIG. 3B .
- the acoustic spacers 203 create spacing between each of the speakers 205 and the protective sleeve 200 , thereby reducing the extent to which the protective sleeve 200 muffles sound from the speakers 205 .
- the acoustic spacer may have any of a variety of shapes and dimensions that allow it to be interposed between the medical device 201 and the protective sleeve 200 .
- the acoustic spacer may have any of a variety of shapes (e.g., oval, circle, rectangle, square, triangle, pentagon, hexagon, octagon, etc.) and dimensions that conform to a portion of the perimeter (or the entire perimeter) of a speaker.
- the acoustic spacers 203 may be integral with a housing of the medical device 201 . In other embodiments, the acoustic spacers 203 may be separate pieces that are securable to the housing of the medical device 201 .
- each of the acoustic spacers 203 may include an adhesive backing to facilitate adhering the acoustic spacers 203 to the medical device 201 .
- the acoustic spacers 203 may be part of a kit that also comprises the protective sleeve 200 , as described in further detail below with respect to the embodiment of FIG. 4C .
- the acoustic spacers may be integral with the body 202 of the protective sleeve 200 and positioned at a location that allows them to be interposed between the medical device 201 and the protective sleeve 200 at a region near one or more speakers.
- FIG. 4B illustrates another embodiment of a protective sleeve 215 for receiving a medical device.
- the sleeve of FIG. 4B is similar to the protective sleeve 200 of FIGS. 2-4 . Thus, common features will not be described here.
- the sleeve 215 of FIG. 4B includes an access opening 217 in an end panel 219 of the protective sleeve 215 .
- the access opening 217 is sized and located so as to provide access to a port of the medical device (not shown), such as a USB port.
- FIG. 4C illustrates a kit 221 including the protective sleeve 215 of FIG. 4B , one of the acoustic spacers 203 of FIG. 3B , and closures 223 , 225 configured to overlie and seal the ingress/egress opening 208 and the access opening 217 .
- a first one of the closures 223 is shaped as a triangle, and is configured to overlie and seal the ingress/egress opening 208 , as shown in FIG. 4D .
- a second one of the closures 225 is shaped as a rectangle (e.g., a square), and is configured to overlie and seal the access opening 217 , as also shown in FIG. 4D .
- Each of the closures 223 , 225 may include an adhesive backing so that the closures 223 , 225 adhere to the sleeve 215 and seal the openings 208 , 217 .
- a disposable peel-away backing paper (not shown) may cover the adhesive backing on each of closures 223 , 225 to prevent the closures 223 , 225 from adhering to any surfaces prior to being secured to the sleeve 215 , and to prevent the adhesive backings from attracting and adhering any debris prior to being secured to the sleeve 215 .
- the closures 223 , 225 may be single-use, such that once a closure 223 , 225 is adhered to the sleeve 215 and later removed from the sleeve 215 , it is not reused thereafter.
- one suitable material for the closures 223 , 225 is FasCal® 400 series multi-purpose screenprint film including a removable, acrylic-based adhesive, available from Avery Dennison.
- the adhesive may be the same for each of the closures 223 , 225 .
- the closures 223 , 225 may comprise an adhesive backing that allows the closures to be peeled off from and re-adhered to the sleeve 215 multiple times.
- FIGS. 5 and 6 illustrate embodiments of protective cases 500 , 600 for receiving a medical device 502 , 602 to reduce the risk of contamination of the medical device 502 , 602 .
- the case 500 , 600 preferably resists penetration of contaminants into an interior of the case 500 , 600 so that such contaminants cannot reach the medical device 502 , 602 contained within the case 500 , 600 .
- Each case 500 , 600 further includes a mechanism that at least discourages, if not prevents, the end user from opening the case 500 , 600 , which would expose the medical device 502 , 602 to contaminants.
- one embodiment comprises a case 500 having a front portion 504 and a back portion 506 .
- the front and back portions 504 , 506 are securable to one another with the medical device 502 contained within an interior space defined by the mated front and back portions 504 , 506 .
- a gasket 508 may be received about a periphery of the junction of the front and back portions 504 , 506 to resist moisture penetration into the interior space of the case 500 .
- the gasket 508 may be of a resilient, moisture resistant material, such as silicone, latex, rubber, and the like.
- the front portion 504 of the case 500 of FIG. 5 includes a transparent or translucent window 510 through which a display 512 of the medical device 502 is visible.
- the window 510 is received within a frame 514 defined by an opening in the front portion 504 . Edges of the window 510 are preferably secured to the frame 514 in a moisture-tight fashion to resist moisture penetration into the interior space of the case 500 .
- the window 510 may be constructed from any suitable material that is durable and transparent or translucent, such as, for example, plastic, polycarbonate, and the like. As illustrated in FIG. 5 , the window 510 is preferably recessed beneath a front surface 516 of the case 500 in order to make it less likely that the window 510 will get scratched.
- the front portion 504 of the case 500 of FIG. 5 further includes a touch pad 518 .
- the location of the touch pad 518 corresponds to the location of a touch pad (not visible in FIG. 5 , but located behind the touch pad 518 ) on the medical device 502 .
- the user can manipulate the touch pad 518 on the case 500 by pressing on any area of it with his or her finger(s) and/or thumb(s), and the digital pressure applied is transmitted to the touch pad on the medical device 502 to thereby enable the user to control the operation of the medical device 502 .
- the touch pad 518 on the case 500 may be constructed of a flexible and resilient material, such as, for example, silicone, latex, rubber, and the like.
- the touch pad 518 on the case 500 may be constructed of a rigid or semi-rigid material, such as, for example, plastic, polycarbonate, and the like.
- Edges of the touch pad 518 on the case 500 are preferably secured to the case 500 in a moisture-tight fashion to resist moisture penetration into the interior space of the case 500 .
- the case 500 of FIG. 5 preferably includes one or more openings or ports (not shown) that enable the user to access any ports on the medical device 502 .
- the medical device 502 may include a Universal Serial Bus (USB) port to enable the medical device 502 to communicate with a computing system through a wired connection, and/or a jack for receiving a plug of a charging cord or adapter.
- USB Universal Serial Bus
- the front and back portions 504 , 506 of the case 500 further include a locking mechanism that deters the user from opening the case 500 .
- a lock 520 is located in an upper right-hand corner of the front and back portions 504 , 506 , and overlaps the junction of front and back portions 504 , 506 .
- the lock 520 prevents the case 500 from being opened.
- the patient is not provided with a key to unlock the lock 520 , so that the patient is discouraged from trying to open the case 500 , which could cause the medical device 502 inside to become contaminated.
- Another person such as a physician who provides the medical device 502 to the patient, preferably possesses the key so that when the patient returns the medical device 502 to the physician at the end of a trial period the physician can open the case 500 and remove the medical device 502 from the case 500 for cleaning and disinfecting.
- the structure of the lock 520 may vary in complexity.
- the lock 520 may comprise something as simple as a removable threaded member (e.g. a bolt, a screw, and the like).
- the lock 520 may be “opened” with a tool (e.g. a screwdriver, an Allen key, and the like) that mates with the head of the threaded member.
- the lock 520 may be more complex, such as one requiring a key to open (e.g. a warded lock, a pin tumbler lock, a wafer tumbler lock, a disc tumbler lock or Abloy lock, a lever tumbler lock, and the like).
- the lock 520 may comprise a combination lock, a time lock, or any other type of lock.
- FIG. 6 illustrates another embodiment of a protective case 600 for receiving a medical device 602 to reduce the risk of contamination of the medical device 602 .
- the case 600 of FIG. 6 includes a front portion 604 and a back portion 606 , a gasket 608 around the junction of the front and back portions 604 , 606 , a window 610 through which the display 612 of the medical device 602 is visible, and a touch pad 614 .
- An end of the case 600 includes a port 616 through which the user may insert a plug of a USB cable. Other ports (not shown) may also be provided for connecting other cables/devices, such as a power cord.
- the case 600 includes a separate plug that is shaped and sized to fit the port 616 and that may be used to provide the medical device 602 with a liquid tight seal when the port 616 is not in use. By establishing a liquid-tight seal through the use of the plug, the case 600 can be cleaned and/or disinfected many times without exposing the medical device 602 to cleaning or disinfecting solutions.
- the case 600 comprises a flap that is integrally formed with the body of the case. The flap may be configured to have an unlocked and a locked position. When in the unlocked position, the flap may be opened to allow access to the port 616 . Conversely, when in the locked positioned, the flap is closed and provides the medical device 600 with a liquid tight seal.
- closures comprising adhesives may be used to seal off the port 616 when it is not in use.
- Each corner of the case 600 includes a threaded opening 618 for receiving a fastening member, such as a screw 620 .
- the screws 620 are received in the threaded openings 618 that extend through the front portion 604 and at least partially through the back portion 606 to secure the front and back portions 604 , 606 to one another.
- the opening through the front portion 604 may not be threaded.
- other fastening members such as may be used instead of the screws 620 .
- the screws 620 provide a deterrent that discourages the patient from opening the case 600 .
- a head of each screw 620 may include a standard feature that can be engaged by one or more common tools, such as a hex key or a screwdriver (flathead or Phillips-head).
- the head of each screw 620 may be configured such that it will only mate with a special tool that may not be readily available to the patient. In either case, the presence of the screws 620 provides a visual reminder to the patient that it is undesirable for him or her to open the case 600 , thereby helping to prevent contamination of the medical device 602 .
- the illustrated shapes and configurations of the cases 500 , 600 of FIGS. 5 and 6 are merely examples that are tailored to receive medical devices 502 , 602 having the illustrated shapes, configurations, features, etc.
- a given case according to the present embodiments would be shaped and configured differently than as illustrated in FIGS. 5 and 6 in order to accommodate such other medical devices.
- Such changes in shape, configuration, etc. are within the scope of the present embodiments.
- the cases 500 , 600 described above with reference to FIGS. 5 and 6 restrict access to the medical device. They also cover the medical device and allow the exterior of the case to be cleaned and disinfected without damaging the functionality of the medical device.
- the case Once attached to the medical device, the case makes the unit water resistant and resistant to common cleaning and disinfection solutions and brushes. Without the case, the unit may be prone to electronics damage from liquid ingress. Further, without the case, the medical device may be prone to being scratched, dented, cracked, etc.
- the protective cases 500 , 600 described above are resistant to common cleaning and disinfecting solutions, such as, for example, water, TERGAZYME®, bleach (e.g. up to 50% concentration), isopropyl alcohol, (ISA), etc.
- the protective cases are preferably made of a durable, impact-resistant plastic, and fit to the contours of the medical device. Once attached to the medical device, the cases cannot be easily removed without a tool. This feature makes the cases a semi-permanent attachment to the medical device and deters the user from removing the medical device from the cases.
- the protective cases have one or more access ports that allow the user to easily access any ports on the medical device. Any ports in the cases are preferably closable or coverable to enhance the water resistance of the cases.
- the protective cases may be used multiple times by multiple patients. The cases are preferably cleaned and disinfected between patients.
- the protective cases 500 , 600 described above are preferably designed to be effectively cleaned and disinfected.
- the following features allow the cases to be effectively cleaned and disinfected: As few grooves as possible, any grooves present are large enough to clean with wipes, as few nooks and crannies as possible, an optional antimicrobial coating, water resistance so that it can be submerged in common cleaning and disinfection solutions, resistant to cleaning brushes, able to be cleaned with moistened wipes (i.e. no brush required), and able to withstand 100 wipes with 10% bleach solution and 100 wipes with 70% isopropyl alcohol.
- the protective cases 500 , 600 described above preferably provide the following characteristics: Ingress Protection Rating of IPX6 or greater, full device functionality inside case (e.g. does not attenuate sound substantially, maintains access to charge port, no impact on RF performance, no impact on IEC 60601 certification of the medical device, etc.), scratch resistance, fog resistance, reduced bulkiness, little to no impact on shipping configuration/validation, and semi-permanent attachment (e.g. can only be removed with a special tool).
- the protective cases described above allow the medical device to be used for multiple patients.
- the protective case is preferably durable so that it may be used multiple times by multiple patients, preferably being cleaned and disinfected between patients.
- the protective cases also preferably protect the medical device from liquid ingress, and preferably protect the medical device from common cleaning and disinfecting solutions.
- the protective cases also prevent the medical device from getting scratched or damaged during normal use.
- the present embodiments are not limited to a receiver.
- the present embodiments are equally adaptable for use with any medical device, such as, for example, a transmitter of a CGM system, any other component of an analyte monitoring system, or any other medical device.
- Certain of the present embodiments comprise methods for cleaning and disinfecting a medical device.
- cleaning the device involves removing soil from the device and preparing the device for disinfection.
- cleaning the medical device reduces protein concentration on surfaces of the medical device to less than about 6.4 ⁇ g/cm 2 , and reduces hemoglobin concentration on surfaces of the medical device to less than about 2.2 ⁇ g/cm 2 .
- Disinfection involves inactivating microbial organisms and/or viruses on the device, rendering the device safe for use by another patient.
- disinfecting the medical device achieves the following reductions in the concentration of various microbes on surfaces of the electronic device, as compared to a pre-disinfected state: duck hepatitis B virus greater than about 3 log 10 reduction, klebsiella pneumonia greater than about 6 log 10 reduction, staphylococcus aureus greater than about 6 log 10 reduction, escherichia coli greater than about 6 log 10 reduction, pseudomonas aeruginosa greater than about 6 log 10 reduction, and mycobacterium terrae greater than about 3 log 10 reduction.
- one method for cleaning a medical device comprises the following steps.
- an operator prepares a cleaning solution by mixing a detergent with potable tap water.
- the detergent may comprise an enzymatic detergent containing one or more of sodium bicarbonate, sodium tripolyphosphate, sodium carbonate, sodium alkybenzene sulfonate, and other non-hazardous ingredients of less than 1% concentration.
- the detergent may comprise TERGAZYME®
- the cleaning solution may comprise a 1% TERGAZYME® solution.
- the 1% TERGAZYME® solution may be produced by, for example, mixing 11 ⁇ 4 TBSP TERGAZYME® with 1 ⁇ 2 gallon of potable tap water.
- the operator applies clean gloves to his or her hands.
- the gloves are preferably resistant to chemicals that may be used in the cleaning method.
- the medical device may include any ports, such as a charging port, a USB (Universal Serial Bus) port, etc.
- the operator ensures that such ports are covered.
- the medical device may include a cover for each port, such as a sliding or swinging door. If the medical device does not include a cover or covers, the operator may cover each port with a temporary, single-use, disposable port cover, which is used to protect the medical device during cleaning and disinfection (e.g. a custom or off-the-shelf plug, tape, and the like).
- the operator moistens a clean, dry wipe or cloth with the cleaning solution and squeezes out any excess liquid.
- the wipe or cloth is also low lint.
- the wipe or cloth may comprise a microfiber wipe or cloth.
- the operator wipes all surfaces of the medical device with the moistened wipe or cloth to apply cleaning solution to all surfaces.
- a method of wiping the medical device may comprise the following steps, in no particular order: folding the wipe into quarters; with a first surface of the wipe, wiping the top of the medical device; refolding the wipe to expose a clean second surface; with the clean second surface wiping all sides of the medical device, refolding the wipe again to expose a clean third surface; and, with the clean third side of the wipe, wiping the bottom of the medical device.
- the operator dips a brush into the cleaning solution and taps or shakes off any excess liquid.
- the bristles of the brush may be a soft material (e.g. nylon and the like) that will not scratch or haze the surfaces of the medical device.
- the operator scrubs all surfaces of the medical device using the brush.
- the operator may scrub the medical device for a minimum duration, such as 15 seconds, 30 seconds, 45 seconds, 60 seconds, etc.
- the operator thoroughly scrubs areas where soil may collect, such as seams and crevices, e.g. around any buttons and/or ports.
- box B 714 the operator repeats boxes B 706 and B 708 .
- box B 716 the operator applies a new pair of clean gloves to his or her hands.
- box B 720 the operator moistens a new clean, dry wipe or cloth with potable tap water and squeezes out any excess liquid. The operator then wipes all surfaces of the medical device with the moistened wipe.
- a method of wiping the medical device may comprise the same steps outlined above with respect to box B 708 .
- box B 722 the operator dries the medical device by wiping with a clean, dry wipe or cloth, which is also preferably low-lint. The operator may refold the wipe to expose a dry surface as needed.
- the operator allows the medical device to dry.
- the medical device may be inverted (keypad and screen facing down) for drying, and any ports thereon may remain open.
- the operator may allow the medical device to dry for a minimum duration, such as 30 minutes, 45 minutes, 60 minutes, etc.
- another method for cleaning a medical device comprises the following steps.
- the operator prepares a cleaning solution.
- the cleaning solution may be prepared according to the ratios/methods described above with respect to box B 700 .
- the operator applies a pair of clean gloves to his or her hands.
- the medical device includes any ports, such as a charging port, a USB (Universal Serial Bus) port, etc., the operator ensures that such ports are covered, similar to box B 704 described above.
- the operator submerges the medical device in the cleaning solution and scrubs all surfaces using a brush while the medical device is submerged.
- the brush and duration of scrubbing may be similar to those described above with respect to boxes B 710 and B 712 .
- the operator leaves the medical device submerged to soak in the cleaning solution for a minimum duration, such as 30 seconds, 45 seconds, 60 seconds, 90 seconds, 2 minutes, etc. In one embodiment, the total duration for which the medical device remains submerged, including scrubbing and soaking, is 3 minutes.
- the operator applies a new pair of clean gloves to his or her hands.
- the operator removes the medical device from the cleaning solution and rinses under running, potable tap water for a minimum duration, such as 5 seconds, 10 seconds, 15 seconds, 20 seconds, 25 seconds, 30 seconds, etc.
- the operator dries the medical device by wiping with a clean, dry wipe or cloth, which is also preferably low-lint. The operator may refold the wipe to expose a dry surface as needed.
- disinfecting the device involves inactivating bacteria, fungi, and/or viruses that may be resident on the medical device.
- the disinfecting methods include a disinfecting solution, which may be, for example, an off-the-shelf spray preparation, which may contain bleach.
- a disinfecting solution may be Dispatch® Hospital Cleaner Disinfectant with Bleach, which advantageously has a short contact time and provides for ease of use.
- the disinfecting solution may be contained in an easy-to-use spray bottle.
- one method for disinfecting a medical device comprises the following steps.
- the operator applies a pair of clean gloves to his or her hands.
- the medical device includes any ports, such as a charging port, a USB (Universal Serial Bus) port, etc.
- the operator ensures that such ports are covered, similar to box B 704 described above.
- the operator places the medical device screen side (front side) up on a clean, flat surface.
- the operator holds the disinfecting solution spray bottle proximate the medical device front surface. For example, in one embodiment the operator may hold the spray bottle 6′′-8′′ from the medical device front surface.
- box B 908 the operator sprays the disinfecting solution onto the medical device front surface until thoroughly wetted.
- the operator may tilt the medical device if necessary to ensure the disinfecting solution has covered the entire front surface.
- box B 910 the operator turns the medical device over so that the back surface is facing up.
- box B 912 the operator wets the medical device back surface with the disinfecting solution in the same manner as in boxes B 906 and B 908 .
- box B 914 the operator wets each side (or edge) of the medical device with the disinfecting solution in the same manner as in boxes B 906 and B 908 . However, in certain embodiments, the operator does not wet (or at least does not directly spray) any side of the medical device that includes at least one port. In box B 916 , the operator allows the medical device to sit wetted for a minimum duration, such as 30 seconds, 45 seconds, 60 seconds, 90 seconds, 2 minutes, 5 minutes, etc.
- the operator wets an absorbent wipe with a second disinfecting solution, such as a 70% isopropyl alcohol (IPA) solution.
- IPA isopropyl alcohol
- the operator wipes down all outside surfaces of the medical device to remove any residue, such as bleach residue.
- the operator uncovers any ports that were covered in box B 902 and wipes or dabs any liquid residue from interior surfaces of the port(s).
- the operator avoids contacting any metal components of the port(s) with the second disinfecting solution so as to avoid causing an electrical short.
- box B 924 the operator wipes the exterior of the medical device completely dry with an absorbent wipe, and dries around any ports with an absorbent wipe if any liquid is observed.
- box B 926 the operator allows the medical device to dry in the same manner as described with respect to box B 724 .
- another method for disinfecting a medical device comprises the following steps.
- the operator applies a pair of clean gloves to his or her hands.
- the operator places the medical device on a flat surface such that any electrical contacts thereon face the flat surface.
- the operator wets the medical device front surface with the disinfecting solution in a similar manner as described above with respect to boxes B 906 and B 908 .
- the operator turns the medical device over so that the electrical contacts face up.
- the operator wets the medical device back surface with the disinfecting solution in the same manner as in boxes B 1004 and B 1006 .
- box B 1012 the operator allows the medical device to sit wetted for a minimum duration, such as 30 seconds, 45 seconds, 60 seconds, 90 seconds, 2 minutes, 5 minutes, etc.
- the operator wipes the medical device completely dry with an absorbent wipe.
- the operator wets an absorbent wipe with a second disinfecting solution, such as a 70% isopropyl alcohol (IPA) solution.
- IPA isopropyl alcohol
- box B 1018 the operator wipes down all outside surfaces of the medical device to remove any residue, such as bleach residue.
- the operator allows the medical device to dry in the same manner as described with respect to box B 724 .
- another method for cleaning a medical device comprises the following steps.
- the operator applies a pair of clean gloves to his or her hands.
- the operator prepares a soaking solution by adding enough bleach solution to a container to submerge the medical device.
- the operator places the medical device on a flat surface such that any electrical contacts thereon face the flat surface.
- the operator wets the medical device front surface with the disinfecting solution in a similar manner as described above with respect to boxes B 906 and B 908 .
- the operator turns the medical device over so that the electrical contacts face up.
- the operator wets the medical device back surface with the disinfecting solution in the same manner as in boxes B 1104 and B 1106 .
- box B 1114 the operator scrubs all surfaces of the medical device using a brush for a minimum duration.
- the operator submerges the medical device in the cleaning solution for a minimum duration.
- the operator removes the medical device from the cleaning solution and rinses it under tap water for a minimum duration.
- the operator wipes the medical device completely dry.
- another method for disinfecting a medical device comprises the following steps.
- the operator applies a pair of clean gloves to his or her hands and goggles over his or her eyes.
- the operator prepares a soaking solution by adding enough bleach solution to a container to submerge the medical device.
- the operator removes a pre-saturated disinfectant (e.g. bleach) wipe from its packaging.
- the operator folds the wipe into a 2′′ ⁇ 2′′ square.
- the operator wipes all surfaces of the medical device by passing over the medical device surface in one direction and then hack in the opposite direction (hack and forth, two passes).
- box B 1210 the operator turns over the wipe to use a clean side for a second back and forth wipe.
- the operator refolds the wipe to use a clean side for a third back and forth wipe.
- the operator turns over the wipe to use a clean side for a fourth back and forth wipe for a total of eight passes, ensuring that all medical device surfaces are covered with disinfectant (e.g. bleach).
- disinfectant e.g. bleach
- box B 1216 the operator places the medical device on a clean, non-porous surface and allows the disinfectant to contact the medical device for a minimum duration.
- box B 1218 the operator places the medical device in the soaking solution for a minimum duration.
- box B 1220 the operator removes the medical device from the soaking solution and rinses it under flowing tap water for a minimum duration.
- box B 1222 the operator wipes the medical device with a cloth until it is completely dry.
- an electronic medical device such as the electronic medical device 201 shown in FIG. 3A , may include a coating of a liquid repellant (e.g., hydrophobic) substance.
- the coating may surround all exposed electrical surfaces of the electronic medical device and seal any cracks, fissures, etc.
- the coating may be invisible to the human eye.
- one suitable coating is available from Liquipel of Santa Ana, Calif.
- tests were conducted comparing the effectiveness of the above-described coating in allowing a medical device to be cleaned and in a variety of cleaning solutions without sustaining damage.
- five DexCom G4® Platinum receivers comprising the test group were coated with Liquipel.
- Another five DexCom G4® Platinum receivers comprising the control group were not coated with Liquipel.
- the study comprised 10 cleaning cycles, in which each cleaning cycle comprised the following steps: (1) wiping the receiver with a detergent; (2) brushing the receiver while exposed to the detergent; (3) wiping the receiver with the detergent; (4) wiping the receiver with water; (5) wiping dry the receiver; (6) setting the receiver for five minutes; (7) spraying the receiver with bleach; (8) setting the receiver for five minutes; (9) wiping dry the receiver; (10) wiping the receiver with alcohol; (11) wiping dry the receiver; (12) setting the receiver for one hour.
- all five receivers underwent the 10 cleaning cycles without suffering any failures.
- Liquipel was effective at protecting the receiver from damage due to liquid ingress.
- Embodiments of the present disclosure are described above and below with reference to flowchart illustrations of methods, apparatus, and computer program products. It will be understood that each block of the flowchart illustrations, and combinations of blocks in the flowchart illustrations, can be implemented by execution of computer program instructions. These computer program instructions may be loaded onto a computer or other programmable data processing apparatus (such as a controller, microcontroller, microprocessor or the like) in a sensor electronics system to produce a machine, such that the instructions which execute on the computer or other programmable data processing apparatus create instructions for implementing the functions specified in the flowchart block or blocks.
- a computer or other programmable data processing apparatus such as a controller, microcontroller, microprocessor or the like
- These computer program instructions may also be stored in a computer-readable memory that can direct a computer or other programmable data processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable memory produce an article of manufacture including instructions which implement the function specified in the flowchart block or blocks.
- the computer program instructions may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide steps for implementing the functions specified in the flowchart block or blocks presented herein.
- the term ‘including’ should be read to mean ‘including, without limitation,’ ‘including but not limited to,’ or the like;
- the term ‘comprising’ as used herein is synonymous with ‘including,’ ‘containing,’ or ‘characterized by,’ and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps;
- the term ‘having’ should be interpreted as ‘having at least;’ the term ‘includes’ should be interpreted as ‘includes but is not limited to;’ the term ‘example’ is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof; adjectives such as ‘known’, ‘normal’, ‘standard’, and terms of similar meaning should not be construed as limiting the item described to a given time period or to an item available as of a given time, but instead should be read to encompass known, normal, or standard technologies that may be available or known now or at any time in the future; and use of terms like ‘preferably,’ ‘preferred,’ ‘desi
- a group of items linked with the conjunction ‘and’ should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as ‘and/or’ unless expressly stated otherwise.
- a group of items linked with the conjunction ‘or’ should not be read as requiring mutual exclusivity among that group, but rather should be read as ‘and/or’ unless expressly stated otherwise.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Optics & Photonics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Abstract
Sleeves and cases for protecting medical devices against contamination, and methods for cleaning and disinfecting medical devices are provided. The various embodiments enable a single medical device to be used by more than one patient successively while reducing the risk of disease transmission from patient to patient.
Description
- Any and all priority claims identified in the Application Data Sheet, or any correction thereto, are hereby incorporated by reference under 37 CFR 1.57. This application is a continuation of U.S. application Ser. No. 15/934,008, filed Mar. 23, 2018, which is a continuation of U.S. application Ser. No. 15/194,242, filed Jun. 27, 2016, now U.S. Pat. No. 9,962,114, which is a continuation of U.S. application Ser. No. 14/505,451, filed Oct. 2, 2014, now U.S. Pat. No. 9,375,065, which claims the benefit of priority of U.S. Provisional Application No. 61/893,822, filed Oct. 21, 2013. Each of the aforementioned applications is incorporated by reference herein in its entirety, and is hereby expressly made a part of this specification.
- The present invention relates to medical devices, and, more particularly to maintaining cleanliness in such devices and to cleaning such devices.
- Diabetes mellitus is a disorder in which the pancreas cannot create sufficient insulin (Type I or insulin dependent) and/or in which insulin is not effective (
Type 2 or non-insulin dependent). In the diabetic state, the victim suffers from high blood sugar, which can cause an array of physiological derangements associated with the deterioration of small blood vessels, for example, kidney failure, skin ulcers, or bleeding into the vitreous of the eye. A hypoglycemic reaction (low blood sugar) can be induced by an inadvertent overdose of insulin, or after a normal dose of insulin or glucose-lowering agent accompanied by extraordinary exercise or insufficient food intake. - Conventionally, a person with diabetes carries a self-monitoring blood glucose (SMBG) monitor, which typically requires uncomfortable finger pricking methods. Due to the lack of comfort and convenience, a person with diabetes normally only measures his or her glucose levels two to four times per day. Unfortunately, such time intervals are so far spread apart that the person with diabetes likely finds out too late of a hyperglycemic or hypoglycemic condition, sometimes incurring dangerous side effects. Glucose levels may be alternatively monitored continuously by a sensor system including an on-skin sensor assembly. The sensor system may have a wireless transmitter that transmits measurement data to a receiver that processes and displays information based on the measurements. Such sensor systems are sometimes referred to as continuous glucose monitors (CGMs).
- In certain scenarios, certain components of a CGM may be used by more than one person. For example, diabetes patients may wish to try a CGM for a limited time on a trial basis, such as when a patient tests a CGM for the first time before committing to using one on a more permanent basis, or when a patient who currently uses a CGM wishes to try a new model, brand, etc. In these scenarios, it is desirable for the CGM to be cleaned and disinfected before it is passed to each patient in order to address concerns associated with blood-borne pathogen disease transmission.
- The present embodiments have several features, no single one of which is solely responsible for their desirable attributes. Without limiting the scope of the present embodiments as expressed by the claims that follow, their more prominent features now will be discussed briefly. After considering this discussion, and particularly after reading the section entitled “Detailed Description,” one will understand how the features of the present embodiments provide the advantages described herein.
- In a first aspect, which is generally applicable (i.e. independently combinable with any of the aspects or embodiments identified herein), particularly with any other embodiment of the first aspect, certain of the present embodiments comprise an enclosure for an electronic medical device. The enclosure comprises a sleeve configured to receive an electronic medical device having a port. The enclosure further comprises a first opening in the sleeve sized and configured to allow for insertion of the electronic medical device into the sleeve and removal of the electronic medical device from the sleeve. The enclosure further comprises a second opening in the sleeve, the second opening being located so as to permit access to the port when the electronic medical device is received within the sleeve. The enclosure further comprises a first cover configured to adhere to a first portion of the sleeve and to cover the first opening. The enclosure further comprises a second cover configured to adhere to a second portion of the sleeve and to cover the second opening.
- In an embodiment of the first aspect, the enclosure further comprises a first adhesive located and configured to secure the first cover to the sleeve at the first portion.
- In an embodiment of the first aspect, the enclosure further comprises a second adhesive located and configured to secure the second cover to the sleeve at the second portion.
- In an embodiment of the first aspect, the first adhesive comprises a first peel strength, the second adhesive comprises a second peel strength, and the first peel strength is different than the second peel strength.
- In an embodiment of the first aspect, the first peel strength is greater than the second peel strength.
- In an embodiment of the first aspect, the first peel strength is great enough to prevent separation of the first cover from the sleeve without tearing the sleeve.
- In an embodiment of the first aspect, the port is at least one of a charging port or a communication port.
- In an embodiment of the first aspect, the communication port is a USB port.
- In an embodiment of the first aspect, the sleeve comprises a material selected from the group consisting of: polyurethane, polyethylene, and low density polyethylene.
- In an embodiment of the first aspect, the sleeve comprises a first portion comprising a first material and a second portion comprising a second material.
- In an embodiment of the first aspect, the second material has greater stiffness than the first material.
- In an embodiment of the first aspect, the first portion comprises a material selected from the group consisting of: polyurethane, polyethylene, and low density polyethylene.
- In an embodiment of the first aspect, the second portion comprises a material selected from the group consisting of: polycarbonate and acrylonitrile butadiene styrene (ABS).
- In an embodiment of the first aspect, the second portion is configured to provide access to the port.
- In an embodiment of the first aspect, the first opening is surrounded by the first portion, and wherein the second opening is surrounded by the second portion.
- In an embodiment of the first aspect, the first opening comprises a first slit that extends in a longitudinal direction, and a second slit that extends in a transverse direction.
- In an embodiment of the first aspect, a first end of the first slit corresponds to a lengthwise center of the second slit.
- In an embodiment of the first aspect, the electronic medical device is configured to display continuous glucose concentration data over a time period.
- In a second aspect, which is generally applicable (i.e. independently combinable with any of the aspects or embodiments identified herein), particularly with any other embodiment of the second aspect, certain of the present embodiments comprise a method for reprocessing a reusable electronic medical device. The method comprises receiving an electronic medical device from a first user, wherein the electronic medical device is contained in a first protective enclosure. The method further comprises removing the electronic medical device from the first protective enclosure. The method further comprises inserting the electronic medical device into a second protective enclosure through an opening in the second protective enclosure. The method further comprises adhering a cover to the second protective enclosure over the opening such that the cover cannot be separated from the second protective enclosure without damaging the second protective enclosure. The method further comprises providing the electronic medical device contained within the second protective enclosure to a second user.
- In an embodiment of the second aspect, the method further comprises creating a disinfected field, wherein removing the electronic medical device from the first protective enclosure and placing the electronic medical device in a second protective enclosure are performed in the disinfected field.
- In an embodiment of the second aspect, removing the electronic medical device from the first protective enclosure requires tearing the first protective enclosure.
- In an embodiment of the second aspect, the method further comprises cleaning and disinfecting the electronic medical device.
- In an embodiment of the second aspect, the electronic medical device is configured to display continuous glucose concentration data over a time period.
- In a third aspect, which is generally applicable (i.e. independently combinable with any of the aspects or embodiments identified herein), particularly with any other embodiment of the third aspect, certain of the present embodiments comprise a case for protecting an electronic medical device. The case comprises a housing defining a cavity configured to receive an electronic medical device having a port. The housing comprises an opening located and configured to allow access to the port when the electronic medical device is contained within the housing. The housing further comprises a lock, which, when in a locked position, is configured to prevent opening of the housing to thereby selectively deter removal of the electronic medical device from the housing.
- In an embodiment of the third aspect, unlocking the lock enables removal of the electronic medical device from the housing.
- An embodiment of the third aspect comprises the case in combination with a key configured to lock and unlock the lock.
- In an embodiment of the third aspect, the housing comprises a first portion and a second portion, and when the first and second portions engage one another and the lock is in the locked position, the first and second portions cannot be separated from one another without damaging at least one of the first and second portions.
- In an embodiment of the third aspect, the housing, when in a closed and locked configuration, meets the IPX7 standard with respect to water penetration.
- In an embodiment of the third aspect, the housing comprises a material selected from the group consisting of: polycarbonate and acrylonitrile butadiene styrene (ABS).
- In an embodiment of the third aspect, the electronic medical device comprises electronics and a display.
- In an embodiment of the third aspect, the electronic medical device is configured to display continuous glucose concentration data over a time period.
- In a fourth aspect, which is generally applicable (i.e. independently combinable with any of the aspects or embodiments identified herein), particularly with any other embodiment of the fourth aspect, certain of the present embodiments comprise a case for protecting an electronic medical device. The case comprises a housing defining a cavity configured to receive an electronic medical device having a port. The housing comprises a first portion, a second portion, and an opening located and configured to allow access to the port when the electronic medical device is contained within the housing. The housing further comprises at least one fastener configured to secure the first and second portions to one another and prevent access to the cavity to thereby selectively deter removal of the electronic medical device from the housing. The fastener, when in a secured position, cannot be removed from the first and second portions by hand.
- In a fifth aspect, which is generally applicable (i.e. independently combinable with any of the aspects or embodiments identified herein), particularly with any other embodiment of the fifth aspect, certain of the present embodiments comprise a method for reprocessing a reusable electronic medical device. The method comprises receiving an electronic medical device from a first user, the electronic medical device including a water resistant protective coating. The method further comprises cleaning the electronic medical device to achieve a concentration in protein on surfaces of the electronic medical device of less than about 6.4 μg/cm2, and a concentration in hemoglobin on surfaces of the electronic medical device of less than about 2.2 μg/cm2. The method further comprises disinfecting the electronic medical device to achieve reductions in duck hepatitis B virus of at least about a 3 log10 reduction, in klebsiella pneumonia of least about a 6 log10 reduction, in staphylococcus aureus of least about a 6 log10 reduction, in escherichia coli of least about a 6 log10 reduction, in pseudomonas aeruginosa of least about a 6 log10 reduction, and in mycobacterium terrae of least about a 3 log10 reduction. At least one of cleaning the electronic medical device or disinfecting the electronic medical device comprises submerging the electronic medical device in a cleaning solution and/or a disinfecting solution. The method further comprises providing the cleaned and disinfected electronic medical device to a second user.
- In an embodiment of the fifth aspect, the water resistant protective coating protects the electronic medical device from damage from liquid ingress.
- In an embodiment of the fifth aspect, the method further comprises drying the electronic medical device.
- In an embodiment of the fifth aspect, the electronic medical device includes at least electronics, a port, a display, and a speaker.
- In an embodiment of the fifth aspect, the electronic medical device is configured to display continuous glucose concentration data over a time period.
- In a seventh aspect, which is generally applicable (i.e. independently combinable with any of the aspects or embodiments identified herein), particularly with any other embodiment of the seventh aspect, certain of the present embodiments comprise a method for cleaning and disinfecting an electronic medical device. The method comprises cleaning the electronic medical device to achieve a concentration in protein on surfaces of the electronic medical device of less than about 6.4 μg/cm2, and a concentration in hemoglobin on surfaces of the electronic medical device of less than about 2.2 μg/cm2. The method further comprises disinfecting the electronic medical device to achieve reductions in duck hepatitis B virus of at least about 3 a log10 reduction, in klebsiella pneumonia of at least about a 6 log10 reduction, in staphylococcus aureus of at least about a 6 log10 reduction, in escherichia coli of at least about a 6 log10 reduction, in pseudomonas aeruginosa of at least about a 6 log10 reduction, and in mycobacterium terrae of at least about a 3 log10 reduction. The method further comprises drying the electronic medical device.
- In an embodiment of the seventh aspect, the electronic medical device comprises at least electronics, a port, a display, and a speaker.
- In an embodiment of the seventh aspect, the electronic medical device is configured to display continuous glucose concentration data over a time period.
- In an eighth aspect, which is generally applicable (i.e. independently combinable with any of the aspects or embodiments identified herein), particularly with any other embodiment of the eighth aspect, certain of the present embodiments comprise a kit for covering and protecting an electronic medical device. The kit comprises a sleeve configured to receive an electronic medical device having a port. The sleeve comprises a first opening sized and configured to allow for insertion of the electronic medical device into the sleeve and removal of the electronic medical device from the sleeve. The sleeve further comprises a second opening in the sleeve, the second opening being located so as to permit access to the port when the electronic medical device is received within the sleeve. The kit further comprises a first closure configured to adhere to a first portion of the sleeve and to overlie and seal the first opening. The kit further comprises a second closure configured to adhere to a second portion of the sleeve and to overlie and seal the second opening.
- In an embodiment of the eighth aspect, the kit further comprises an acoustic spacer configured to be interposed between the sleeve and the electronic medical device to create a space between the sleeve and the electronic medical device.
- In an embodiment of the eighth aspect, each of the first and second closures includes an adhesive backing.
- In an embodiment of the eighth aspect, the electronic medical device is configured to display continuous glucose concentration data over a time period.
- The present embodiments now will be discussed in detail with an emphasis on highlighting the advantageous features. These embodiments depict the novel and non-obvious apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device, shown in the accompanying drawings, which are for illustrative purposes only. These drawings include the following figures, in which like numerals indicate like parts:
-
FIG. 1 is a schematic view of a continuous analyte sensor system attached to a host and communicating with other devices; -
FIG. 2 is a rear perspective view of one embodiment of a protective sleeve for receiving a medical device; -
FIG. 3A is a front perspective view of the protective sleeve ofFIG. 2 with a medical device received therein; -
FIG. 3B is a front perspective view of the protective sleeve and the medical device ofFIG. 3A in combination with acoustic spacers; -
FIG. 4A is a rear perspective view of the protective sleeve ofFIG. 2 ; -
FIG. 4B is a rear perspective view of another embodiment of a protective sleeve for receiving a medical device; -
FIG. 4C is perspective view of a kit including the protective sleeve ofFIG. 4B , one of the acoustic spacers ofFIG. 3B , and closures configured for use with the sleeve ofFIG. 4B ; -
FIG. 4D is a rear perspective view of the sleeve ofFIG. 4B and the closures ofFIG. 4C ; -
FIG. 5 is a front perspective view of one embodiment of a case for receiving a medical device: -
FIG. 6 is a front perspective view of a other embodiment of a case for receiving a medical device; and -
FIGS. 7 and 8 are flowcharts illustrating embodiments of methods for cleaning a medical device; -
FIGS. 9 and 10 are flowcharts illustrating embodiments of methods for disinfecting a medical device; -
FIG. 11 is a flowchart illustrating another embodiment of a method for cleaning a medical device; and -
FIG. 12 is a flowchart illustrating another embodiment of a method for disinfecting a medical device. - The following detailed description describes the present embodiments with reference to the drawings. In the drawings, reference numbers label elements of the present embodiments. These reference numbers are reproduced below in connection with the discussion of the corresponding drawing features.
- The present embodiments are described below with reference to the figures. These figures, and their written descriptions, may indicate that certain components of the apparatus are formed integrally, and certain other components are formed as separate pieces. Those of ordinary skill in the art will appreciate that components shown and described herein as being formed integrally may in alternative embodiments be formed as separate pieces. Those of ordinary skill in the art will further appreciate that components shown and described herein as being formed as separate pieces may in alternative embodiments be formed integrally. Further, as used herein the term integral describes a single unitary piece.
- The preferred embodiments relate to the use of an analyte sensor that measures a concentration of glucose or a substance indicative of the concentration or presence of the analyte. In some embodiments, the analyte sensor is a continuous device, for example a subcutaneous, transdermal, transcutaneous, and/or intravascular (e.g., intravenous) device. In some embodiments, the device can analyze a plurality of intermittent blood samples. The analyte sensor can use any method of glucose-measurement, including enzymatic, chemical, physical, electrochemical, optical, optochemical, fluorescence-based, spectrophotometric, spectroscopic (e.g., optical absorption spectroscopy, Raman spectroscopy, etc.), polarimetric, calorimetric, iontophoretic, radiometric, and the like.
- The analyte sensor can use any known method, including invasive, minimally invasive, and non-invasive sensing techniques, to provide a data stream indicative of the concentration of the analyte in a host. The data stream is typically a raw data signal that is used to provide a useful value of the analyte to a user, such as a patient or health care professional (e.g., doctor), who may be using the sensor.
- Although much of the description and examples are drawn to a glucose sensor, the systems and methods of the preferred embodiments can be applied to any measurable analyte. In some preferred embodiments, the analyte sensor is a glucose sensor capable of measuring the concentration of glucose in a host. One example embodiment is described below, which utilizes an implantable glucose sensor. However, it should be understood that the devices and methods described herein can be applied to any device capable of detecting a concentration of analyte and providing an output signal that represents the concentration of the analyte.
- In one preferred embodiment, the analyte sensor is an implantable glucose sensor, such as described with reference to U.S. Pat. No. 6,001,067 and U.S. Patent Publication No. US-2011-0027127-A1. In another preferred embodiment, the analyte sensor is a transcutaneous glucose sensor, such as described with reference to U.S. Patent Publication No. US-2006-0020187-A1. In yet another preferred embodiment, the analyte sensor is a dual electrode analyte sensor, such as described with reference to U.S. Patent Publication No. US-2009-0137887-A1. In still other embodiments, the sensor is configured to be implanted in a host vessel or extracorporeally, such as is described in U.S. Patent Publication No. US-2007-0027385-A1.
- The membrane system can be deposited on the exposed electroactive surfaces using any variety of known thin film techniques (for example, vapor deposition, spraying, printing (e.g., pad printing), electro-depositing, dipping, sputtering deposition, spin coating, powder coating, and the like). In alternative embodiments, however, other vapor deposition processes (e.g., physical and/or chemical vapor deposition processes) can be useful for providing one or more of the insulating and/or membrane layers, including ultrasonic vapor deposition, electrostatic deposition, evaporative deposition, deposition by sputtering, pulsed laser deposition, high velocity oxygen fuel deposition, thermal evaporator deposition, electron beam evaporator deposition, deposition by reactive sputtering molecular beam epitaxy, atmospheric pressure chemical vapor deposition (CVD), atomic layer CVD, hot wire CVD, low-pressure CVD, microwave plasma-assisted CVD, plasma-enhanced CVD, rapid thermal CVD, remote plasma-enhanced CVD, and ultra-high vacuum CVD, for example. However, the membrane system can be disposed over (or deposited on) the electroactive surfaces using any known method, as will be appreciated by one skilled in the art.
- The term “analyte” as used herein is a broad term, and is to be given its ordinary and customary meaning to a person of ordinary skill in the art (and it is not to be limited to a special or customized meaning), and refers without limitation to a substance or chemical constituent in a biological fluid (for example, blood, interstitial fluid, cerebral spinal fluid, lymph fluid or urine) that can be analyzed. Analytes may include naturally occurring substances, artificial substances, metabolites, and/or reaction products. In some embodiments, the analyte for measurement by the sensor heads, devices, and methods disclosed herein is glucose. However, other analytes are contemplated as well, including but not limited to lactate or lactic acid; cardiac markers; ketone bodies; acetone; acetoacetic acid; beta hydroxybutyric acid; glucagon, acetyl Co A; intermediaries in the Citric Acid Cycle; choline, testosterone; creatinine; triglycerides; sodium; potassium; chloride; bicarbonate; total protein; alkaline phosphatase; calcium; phosphorus; PO2; PCO2; bilirubin (direct and total); red blood cell count; white blood cell count; hemoglobin; hemactocrit; lymphocytes; monocytes; eosinophils; basophils; c-reactive protein; cryoglobulins; fibrinogens; ACTH; aldosterone; ammonia; beta-HCG; magnesium; copper; iron; total cholesterol; low density lipoproteins; high density lipoproteins; lipoprotein A; T4 (total and free); TSH; FSH; LH; ACTH; hepatitis BE antigen; hepatitis B surface antigen; hepatitis A antibody; hepatitis C antibody; acarboxyprothrombin; acylcarnitine; adenine phosphoribosyl transferase; adenosine deaminase; albumin; alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, tryptophan); andrenostenedione; antipyrine; arabinitol enantiomers; arginase; benzoylecgonine (cocaine); biotinidase; biopterin; c-reactive protein; carnitine; carnosinase; CD4; ceruloplasmin; chenodeoxycholic acid; chloroquine; cholesterol; cholinesterase; conjugated 1-ß hydroxy-cholic acid; cortisol; creatine kinase; creatine kinase MM isoenzyme; cyclosporin A; d-penicillamine; de-ethylchloroquine; dehydroepiandrosterone sulfate; DNA (acetylator polymorphism, alcohol dehydrogenase, alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, analyte-6-phosphate dehydrogenase, hemoglobinopathies A, S, C, and E, D-Punjab, beta-thalassemia, hepatitis B virus, HCMV, HIV-1, HTLV-1, Leber hereditary optic neuropathy, MCAD, RNA, PKU, Plasmodium vivax, sexual differentiation, 21-deoxycortisol); desbutylhalofantrine; dihydropteridine reductase; diptheria/tetanus antitoxin; erythrocyte arginase; erythrocyte protoporphyrin; esterase D; fatty acids/acylglycines; free ß-human chorionic gonadotropin; free erythrocyte porphyrin; free thyroxine (FT4); free tri-iodothyronine (FT3); fumarylacetoacetase; galactose/gal-1-phosphate; galactose-1-phosphate uridyltransferase; gentamicin; analyte-6-phosphate dehydrogenase; glutathione; glutathione perioxidase; glycocholic acid; glycosylated hemoglobin; halofantrine; hemoglobin variants; hexosaminidase A; human erythrocyte carbonic anhydrase I; 17 alpha-hydroxyprogesterone; hypoxanthine phosphoribosyl transferase; immunoreactive trypsin; lactate; lead; lipoproteins ((a), B/A-1, ß); lysozyme; mefloquine; netilmicin; phenobarbitone; phenytoin; phytanic/pristanic acid; progesterone; prolactin; prolidase; purine nucleoside phosphorylase; quinine; reverse tri-iodothyronine (rT3); selenium; serum pancreatic lipase; sissomicin; somatomedin C; specific antibodies (adenovirus, anti-nuclear antibody, anti-zeta antibody, arbovirus, Aujeszky's disease virus, dengue virus, Dracunculus medinensis, Echinococcus granulosus, Entamoeba histolytica, enterovirus, Giardia duodenalisa, Helicobacter pylori, hepatitis B virus, herpes virus, HIV-1, IgE (atopic disease), influenza virus, Leishmania donovani, leptospira, measles/mumps/rubella, Mycobacterium leprae, Mycoplasma pneumoniae, Myoglobin, Onchocerca volvulus, parainfluenza virus, Plasmodium falciparum, poliovirus, Pseudomonas aeruginosa, respiratory syncytial virus, rickettsia (scrub typhus), Schistosoma mansoni, Toxoplasma gondii, Trepenoma pallidium, Trypanosoma cruzi/rangeli, vesicular stomatis virus, Wuchereria bancrofti, yellow fever virus); specific antigens (hepatitis B virus, HIV-1); succinylacetone; sulfadoxine; theophylline; thyrotropin (TSH); thyroxine (T4); thyroxine-binding globulin; trace elements; transferrin; UDP-galactose-4-epimerase; urea; uroporphyrinogen I synthase; vitamin A; white blood cells; and zinc protoporphyrin. Salts, sugar, protein, fat, vitamins, and hormones naturally occurring in blood or interstitial fluids may also constitute analytes in certain embodiments. The analyte may be naturally present in the biological fluid, for example, a metabolic product, a hormone, an antigen, an antibody, and the like. Alternatively, the analyte may be introduced into the body, for example, a contrast agent for imaging, a radioisotope, a chemical agent, a fluorocarbon-based synthetic blood, or a drug or pharmaceutical composition, including but not limited to insulin; ethanol; cannabis (marijuana, tetrahydrocannabinol, hashish); inhalants (nitrous oxide, amyl nitrite, butyl nitrite, chlorohydrocarbons, hydrocarbons); cocaine (crack cocaine); stimulants (amphetamines, methamphetamines, Ritalin, Cylert, Preludin, Didrex, PreState, Voranil, Sandrex, Plegine); depressants (barbituates, methaqualone, tranquilizers such as Valium, Librium, Miltown, Serax, Equanil, Tranxene); hallucinogens (phencyclidine, lysergic acid, mescaline, peyote, psilocybin); narcotics (heroin, codeine, morphine, opium, meperidine, Percocet, Percodan, Tussionex, Fentanyl, Darvon, Talwin, Lomotil); designer drugs (analogs of fentanyl, meperidine, amphetamines, methamphetamines, and phencyclidine, for example, Ecstasy); anabolic steroids; and nicotine. The metabolic products of drugs and pharmaceutical compositions are also contemplated analytes. Analytes such as neurochemicals and other chemicals generated within the body may also be analyzed, such as, for example, ascorbic acid, uric acid, dopamine, noradrenaline, 3-methoxytyramine (3MT), 3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 5-hydroxytryptamine (5HT), and 5-hydroxyindoleacetic acid (FHIAA).
- For illustrative purposes, reference will now be made to
FIG. 1 , which is an example environment in which some embodiments described herein may be implemented. Here, ananalyte monitoring system 100 includes a continuousanalyte sensor system 8. Continuousanalyte sensor system 8 includes asensor electronics module 12 and acontinuous analyte sensor 10. Thesystem 100 can also include other devices and/or sensors, such as amedicament delivery pump 2 and a reference analyte meter 4, as illustrated inFIG. 1 . Thecontinuous analyte sensor 10 may be physically connected tosensor electronics module 12 and may be integral with (e.g., non-releasably attached to) or releasably attachable to thecontinuous analyte sensor 10. Alternatively, thecontinuous analyte sensor 10 may be physically separate tosensor electronics module 12, but electronically coupled via inductive coupling or the like. Further, thesensor electronics module 12,medicament delivery pump 2, and/or analyte reference meter 4 may communicate with one or more additional devices, such as any or all of 14, 16, 18, 20, and 21.display devices - The
system 100 ofFIG. 1 also includes a cloud-basedprocessor 22 configured to analyze analyte data, medicament delivery data, and/or other patient related data provided overnetwork 24 directly or indirectly from one or more ofsensor system 8,medicament delivery pump 2, reference analyte meter 4, and display devices 14-21. Based on the received data, theprocessor 22 can further process the data, generate reports providing statistic based on the processed data, trigger notifications to electronic devices associated with the host or caretaker of the host, or provide processed information to any of the other devices ofFIG. 1 . In some example implementations, the cloud-basedprocessor 22 comprises one or more servers. If the cloud-basedprocessor 22 comprises multiple servers, the servers can be either geographically local or separate from one another. Thenetwork 24 can include any wired and wireless communication medium to transmit data, including WiFi networks, cellular networks, the Internet and any combinations thereof. - It should be understood that although the example implementation described with respect to
FIG. 1 refers to analyte data being received byprocessor 22, other types of data processed and raw data may be received as well. - In some example implementations, the
sensor electronics module 12 may include electronic circuitry associated with measuring and processing data generated by thecontinuous analyte sensor 10. This generated continuous analyte sensor data may also include algorithms, which can be used to process and calibrate the continuous analyte sensor data, although these algorithms may be provided in other ways as well. Thesensor electronics module 12 may include hardware, firmware, software, or a combination thereof to provide measurement of levels of the analyte via a continuous analyte sensor, such as a continuous glucose sensor. - The
sensor electronics module 12 may, as noted, couple (e.g., wirelessly and the like) with one or more devices, such as any or all of 14, 16, 18, 20, and 21. Thedisplay devices 14, 16, 18, 20, and/or 21 may be configured for processing and presenting information, such sensor information transmitted by thedisplay devices sensor electronics module 12 for display at the display device. The 14, 16, 18, 20, and 21 can also trigger alarms based on the analyte sensor data.display devices - In
FIG. 1 ,display device 14 is a key fob-like display device,display device 16 is a hand-held application-specific computing device 16 (e.g. the DexCom G4® Platinum receiver commercially available from DexCom, Inc.),display device 18 is a general purpose smart phone or tablet computing device 20 (e.g. an Apple® iPhone®, iPad®, or iPod Touch® commercially available from Apple, Inc.),display device 20 is acomputer workstation 20, anddisplay device 21 is any wearable. In some example implementations, the relatively small, key fob-like display device 14 may be a computing device embodied in a wrist watch, a belt, a necklace, a pendent, a piece of jewelry, an adhesive patch, a pager, a key fob, a plastic card (e.g., credit card), an identification (ID) card, and/or the like. Thissmall display device 14 may include a relatively small display (e.g., smaller than the display device 18) and may be configured to display a limited set of displayable sensor information, such as anumerical value 26 and/or anarrow 28. In contrast, 16, 18, and 20 can be larger display devices that can be capable of displaying a larger set of displayable information, such as adisplay devices trend graph 30 depicted on the hand-heldreceiver 16 in addition to other information such as a numerical value and arrow. - It is understood that any other user equipment (e.g. computing devices) configured to at least present information (e.g., a medicament delivery information, discrete self-monitoring analyte readings, heart rate monitor, caloric intake monitor, and the like) can be used in addition or instead of those discussed with reference to
FIG. 1 . - In some example implementations of
FIG. 1 , thecontinuous analyte sensor 10 comprises a sensor for detecting and/or measuring analytes, and thecontinuous analyte sensor 10 may be configured to continuously detect and/or measure analytes as a non-invasive device, a subcutaneous device, a transdermal device, and/or an intravascular device. In some example implementations, thecontinuous analyte sensor 10 may analyze a plurality of intermittent blood samples, although other analytes may be used as well. - In some example implementations of
FIG. 1 , thecontinuous analyte sensor 10 may comprise a glucose sensor configured to measure glucose in the blood using one or more measurement techniques, such as enzymatic, chemical, physical, electrochemical, spectrophotometric, polarimetric, calorimetric, iontophoretic, radiometric, immunochemical, and the like. In implementations in which thecontinuous analyte sensor 10 includes a glucose sensor, the glucose sensor may be comprise any device capable of measuring the concentration of glucose and may use a variety of techniques to measure glucose including invasive, minimally invasive, and non-invasive sensing techniques (e.g., fluorescent monitoring), to provide a data, such as a data stream, indicative of the concentration of glucose in a host. The data stream may be raw data signal, which is converted into a calibrated and/or filtered data stream used to provide a value of glucose to a host, such as a user, a patient, or a caretaker (e.g., a parent, a relative, a guardian, a teacher, a doctor, a nurse, or any other individual that has an interest in the wellbeing of the host). Moreover, thecontinuous analyte sensor 10 may be implanted as at least one of the following types of sensors: an implantable glucose sensor, a transcutaneous glucose sensor, implanted in a host vessel or extracorporeally, a subcutaneous sensor, a refillable subcutaneous sensor, an intravascular sensor. - In some implementations of
FIG. 1 , the continuousanalyte sensor system 8 includes a DexCom G4® Platinum glucose sensor and transmitter commercially available from DexCom, Inc., for continuously monitoring a host's glucose levels. - As discussed above, medical devices may in some cases be used by more than one patient. For example, the
medical device receiver 16 ofFIG. 1 may be used by multiple patients on a trial basis so that each patient can determine whether a particular model of receiver is the right one for him or her before committing to buying one. To reduce the spread of disease, it is desirable for such medical devices to be in a clean and disinfected state when passed on to each patient. The present embodiments, described in detail below, provide various apparatus and methods for maintaining a medical device in a cleaned and disinfected state, and for cleaning and disinfecting a medical device after use. -
FIGS. 2-4A illustrate one embodiment of aprotective sleeve 200 for receiving an electronic medical device 201 (FIG. 3A ) to reduce the risk of contamination of themedical device 201. Under typical use, thesleeve 200 preferably resists penetration of contaminants into an interior of thesleeve 200 so that such contaminants cannot reach themedical device 201 contained within thesleeve 200. In some embodiments, thesleeve 200 may be designed for a single use, after which thesleeve 200 may be disposed of. In other embodiments, thesleeve 200 may be designed for multiple uses, which may comprise cleaning and disinfecting between uses. - With reference to
FIG. 2 , thesleeve 200 comprises abody portion 202 defining aninternal space 204 for receiving themedical device 201. Thebody portion 202 is sized and shaped such that it can be formed to have a shape such that thespace 204 is substantially the same size and shape as themedical device 201, so that thesleeve 200 fits over themedical device 201 in a closely conforming fashion, as shown inFIGS. 3A and 3B . Thebody portion 202 may also be sized so that thespace 204 is slightly smaller than themedical device 201, so that thesleeve 200 stretches in order to fit over themedical device 201 in a closely conforming fashion. In the illustrated embodiment, thesleeve 200 is shaped substantially as a rectangular parallelepiped when expanded, but in other embodiments the sleeve can be designed to have any shape to fit any of a variety of medical devices. - With reference to
FIG. 4 , aback panel 206 of thesleeve 200 includes an ingress/egress opening 208 through which themedical device 201 may be passed to insert themedical device 201 into thesleeve 200 and to withdraw themedical device 201 from thesleeve 200. In the illustrated embodiment, theopening 208 comprises afirst slit 210 in theback panel 206 that runs substantially parallel to a longitudinal axis of thesleeve 200, and asecond slit 212 in theback panel 206 that runs substantially perpendicular to the longitudinal axis of thesleeve 200, and which intersects afirst end 214 of thefirst slit 210. Theopening 208 is thus substantially T-shaped. However, in other embodiments theopening 208 can have any of a variety of configurations. - With further reference to
FIG. 4 , anend panel 216 of thesleeve 200 includes an access opening 218 through which one or more ports of themedical device 201 may be accessed. For example, themedical device 201 may include a Universal Serial Bus (USB) port 220 (FIG. 3A ) to enable themedical device 201 to communicate with a computing system through a wired connection, and/or a jack (not shown) for receiving a plug of a charging cord or adapter (not shown). The access opening 218 thus enables themedical device 201 to be charged and/or connected to a computing system without the need to remove thesleeve 200. - The
sleeve 200 is preferably constructed of a durable material (e.g., an elastic polymer) that can stretch and conform to the contours of themedical device 201. However, in some embodiments, thesleeve 200 may be formed of a rigid or semi-rigid material. In yet other embodiments, the sleeve may comprise one or more portions that comprise a rigid or semi-rigid material and one or more other portions that comprise an elastic material. In some embodiments thesleeve 200 may be transparent or translucent, while in other embodiments thesleeve 200 may be opaque. For example, thesleeve 200 may comprise any of a variety of materials, including, but not limited to, polyurethane, polypropylene, polyethylene, polyethylene terephthalate, polyvinyl chloride, polyvinylidene chloride, polystyrene, polyamide, polycarbonate, silicone, neoprene, and copolymers or combinations thereof. The material of thesleeve 200 is preferably resistant to common cleaning and disinfecting solutions, such as, for example, water, an enzyme active powdered detergent that is a concentrated anionic detergent, such as TERGAZYME®, bleach (e.g. up to 50% concentration), isopropyl alcohol (ISA), Pine Quat 64 Disinfectant (e.g. 100% concentration), 64 General Purpose Disinfectant (e.g. 100% concentration), VirkonS (e.g. up to 10% concentration to warm water), Ali-Flex (e.g. 100% concentration), Windex (e.g. 100% concentration), Softsoap (e.g. approximately 2% concentration to water), etc. - With further reference to
FIG. 4 , theback panel 206 of thesleeve 200 comprises afirst closure 222 adjacent the ingress/egress opening 208 and asecond closure 224 adjacent theaccess opening 218. Each of the illustrated 222, 224 is substantially rectangular, but in other embodiments they could be any shape. Theclosures first closure 222 is configured to selectively cover the ingress/egress opening 208, and thesecond closure 224 is configured to selectively cover the access opening 218, as described below. - The
first closure 222 comprises a separate piece that is secured to theback panel 206 along afirst edge 226, while thesecond closure 224 comprises a separate piece that is secured to theend panel 216 along afirst edge 228. However, in alternative embodiments either or both of the 222, 224 may be integrally formed with theclosures body 202. Dimensions of each 222, 224 are sufficient to enable eachclosure 222, 224 to completely cover itsclosure 208, 218. Adhesive(s) may be applied to either or both of the first andrespective opening 222, 224 and/or to either or both of thesecond closures back panel 206 and theend panel 216. The adhesive(s) enable the 222, 224 to be secured to theirclosures 206, 216 while covering theirrespective panels 208, 218.respective openings - In one embodiment, a
first adhesive 230 is applied to thefirst closure 222 and/or to theback panel 206, and asecond adhesive 232 is applied to thesecond closure 224, and/or to theend panel 216, and/or to theback panel 206 adjacent the access opening 218, and the first and 230, 232 have different adhesion strengths. For example, thesecond adhesives first adhesive 230 may have greater adhesion strength than thesecond adhesive 232. In such an embodiment, thesecond closure 224 may be repeatedly adhered to and peeled from the back/end panel(s) 206, 216 so that any ports covered by thesecond closure 224 can be repeatedly accessed and the access opening 218 subsequently resealed. But thefirst adhesive 230 is preferably strong enough that thefirst closure 222, once sealed over the ingress/egress opening 208, cannot be peeled away from theback panel 206 without tearing thefirst closure 222 and/or theback panel 206. This feature discourages the end user from trying to remove themedical device 201 from thesleeve 200, which could cause themedical device 201 to become soiled or contaminated. In some embodiments, each of the 222, 224 comprises an adhesive on the side that is to be adhered to theclosures sleeve 200. A disposable peel-away backing paper (not shown) may cover the adhesive backing on each of the 222, 224 to prevent theclosures 222, 224 from adhering to any surfaces prior to being secured to theclosures sleeve 200, and to prevent the adhesive backings from attracting and adhering any debris prior to being secured to thesleeve 200. - The
protective sleeve 200 described above allows themedical device 201 to be used for multiple patients, with a newprotective sleeve 200 applied to themedical device 201 for each patient. Theprotective sleeve 200 is disposable and is intended for single-patient use. Using a newprotective sleeve 200 for each patient helps prevent cross-contamination from patient to patient. Theprotective sleeve 200 also protects themedical device 201 from contamination and liquid ingress. -
FIG. 3B illustrates theprotective sleeve 200 and themedical device 201 in combination withacoustic spacers 203. In the illustrated embodiment, themedical device 201 includes a pair ofspeakers 205 located atopposite corners 207 of one end of themedical device 201. Thespeakers 205 are configured to emit audible tones, such as tones to alert the patient to various conditions. Theprotective sleeve 200 overlies thespeakers 205. To reduce the attenuation of sound emanating from thespeakers 205, theacoustic spacers 203 may be interposed between themedical device 201 and theprotective sleeve 200 at thecorners 207, as further discussed below. - Each
acoustic spacer 203 includes first and 209, 211 that extend in perpendicular directions from asecond segments junction 213. Eachacoustic spacer 203 is oriented such that thejunction 213 aligns with itsrespective corner 207 of themedical device 201, with the first and 209, 211 extending along perpendicular sides of thesecond segments medical device 201, as shown inFIG. 3B . Theacoustic spacers 203 create spacing between each of thespeakers 205 and theprotective sleeve 200, thereby reducing the extent to which theprotective sleeve 200 muffles sound from thespeakers 205. - In other embodiments, the acoustic spacer may have any of a variety of shapes and dimensions that allow it to be interposed between the
medical device 201 and theprotective sleeve 200. For example, in some embodiments the acoustic spacer may have any of a variety of shapes (e.g., oval, circle, rectangle, square, triangle, pentagon, hexagon, octagon, etc.) and dimensions that conform to a portion of the perimeter (or the entire perimeter) of a speaker. - In certain embodiments, the
acoustic spacers 203 may be integral with a housing of themedical device 201. In other embodiments, theacoustic spacers 203 may be separate pieces that are securable to the housing of themedical device 201. For example, each of theacoustic spacers 203 may include an adhesive backing to facilitate adhering theacoustic spacers 203 to themedical device 201. Theacoustic spacers 203 may be part of a kit that also comprises theprotective sleeve 200, as described in further detail below with respect to the embodiment ofFIG. 4C . In yet other embodiments, the acoustic spacers may be integral with thebody 202 of theprotective sleeve 200 and positioned at a location that allows them to be interposed between themedical device 201 and theprotective sleeve 200 at a region near one or more speakers. -
FIG. 4B illustrates another embodiment of aprotective sleeve 215 for receiving a medical device. The sleeve ofFIG. 4B is similar to theprotective sleeve 200 ofFIGS. 2-4 . Thus, common features will not be described here. Thesleeve 215 ofFIG. 4B includes an access opening 217 in anend panel 219 of theprotective sleeve 215. Theaccess opening 217 is sized and located so as to provide access to a port of the medical device (not shown), such as a USB port. -
FIG. 4C illustrates akit 221 including theprotective sleeve 215 ofFIG. 4B , one of theacoustic spacers 203 ofFIG. 3B , and 223, 225 configured to overlie and seal the ingress/closures egress opening 208 and theaccess opening 217. A first one of theclosures 223 is shaped as a triangle, and is configured to overlie and seal the ingress/egress opening 208, as shown inFIG. 4D . A second one of theclosures 225 is shaped as a rectangle (e.g., a square), and is configured to overlie and seal the access opening 217, as also shown inFIG. 4D . Each of the 223, 225 may include an adhesive backing so that theclosures 223, 225 adhere to theclosures sleeve 215 and seal the 208, 217. A disposable peel-away backing paper (not shown) may cover the adhesive backing on each ofopenings 223, 225 to prevent theclosures 223, 225 from adhering to any surfaces prior to being secured to theclosures sleeve 215, and to prevent the adhesive backings from attracting and adhering any debris prior to being secured to thesleeve 215. - The
223, 225 may be single-use, such that once aclosures 223, 225 is adhered to theclosure sleeve 215 and later removed from thesleeve 215, it is not reused thereafter. In such embodiments, one suitable material for the 223, 225 is FasCal® 400 series multi-purpose screenprint film including a removable, acrylic-based adhesive, available from Avery Dennison. In such embodiments, the adhesive may be the same for each of theclosures 223, 225. In other embodiments, theclosures 223, 225 may comprise an adhesive backing that allows the closures to be peeled off from and re-adhered to theclosures sleeve 215 multiple times. -
FIGS. 5 and 6 illustrate embodiments of 500, 600 for receiving aprotective cases 502, 602 to reduce the risk of contamination of themedical device 502, 602. Themedical device 500, 600 preferably resists penetration of contaminants into an interior of thecase 500, 600 so that such contaminants cannot reach thecase 502, 602 contained within themedical device 500, 600. Eachcase 500, 600 further includes a mechanism that at least discourages, if not prevents, the end user from opening thecase 500, 600, which would expose thecase 502, 602 to contaminants.medical device - With reference to
FIG. 5 , one embodiment comprises acase 500 having afront portion 504 and aback portion 506. The front and 504, 506 are securable to one another with theback portions medical device 502 contained within an interior space defined by the mated front and 504, 506. Aback portions gasket 508 may be received about a periphery of the junction of the front and 504, 506 to resist moisture penetration into the interior space of theback portions case 500. Thegasket 508 may be of a resilient, moisture resistant material, such as silicone, latex, rubber, and the like. - The
front portion 504 of thecase 500 ofFIG. 5 includes a transparent ortranslucent window 510 through which adisplay 512 of themedical device 502 is visible. Thewindow 510 is received within aframe 514 defined by an opening in thefront portion 504. Edges of thewindow 510 are preferably secured to theframe 514 in a moisture-tight fashion to resist moisture penetration into the interior space of thecase 500. Thewindow 510 may be constructed from any suitable material that is durable and transparent or translucent, such as, for example, plastic, polycarbonate, and the like. As illustrated inFIG. 5 , thewindow 510 is preferably recessed beneath afront surface 516 of thecase 500 in order to make it less likely that thewindow 510 will get scratched. - The
front portion 504 of thecase 500 ofFIG. 5 further includes atouch pad 518. The location of thetouch pad 518 corresponds to the location of a touch pad (not visible inFIG. 5 , but located behind the touch pad 518) on themedical device 502. The user can manipulate thetouch pad 518 on thecase 500 by pressing on any area of it with his or her finger(s) and/or thumb(s), and the digital pressure applied is transmitted to the touch pad on themedical device 502 to thereby enable the user to control the operation of themedical device 502. For example, in some embodiments thetouch pad 518 on thecase 500 may be constructed of a flexible and resilient material, such as, for example, silicone, latex, rubber, and the like. In other embodiments thetouch pad 518 on thecase 500 may be constructed of a rigid or semi-rigid material, such as, for example, plastic, polycarbonate, and the like. - Edges of the
touch pad 518 on thecase 500 are preferably secured to thecase 500 in a moisture-tight fashion to resist moisture penetration into the interior space of thecase 500. Thecase 500 ofFIG. 5 preferably includes one or more openings or ports (not shown) that enable the user to access any ports on themedical device 502. For example, themedical device 502 may include a Universal Serial Bus (USB) port to enable themedical device 502 to communicate with a computing system through a wired connection, and/or a jack for receiving a plug of a charging cord or adapter. - The front and
504, 506 of theback portions case 500 further include a locking mechanism that deters the user from opening thecase 500. For example, in the illustrated embodiment, alock 520 is located in an upper right-hand corner of the front and 504, 506, and overlaps the junction of front andback portions 504, 506. When in a locked position, theback portions lock 520 prevents thecase 500 from being opened. Preferably, the patient is not provided with a key to unlock thelock 520, so that the patient is discouraged from trying to open thecase 500, which could cause themedical device 502 inside to become contaminated. Another person, such as a physician who provides themedical device 502 to the patient, preferably possesses the key so that when the patient returns themedical device 502 to the physician at the end of a trial period the physician can open thecase 500 and remove themedical device 502 from thecase 500 for cleaning and disinfecting. - The structure of the
lock 520 may vary in complexity. For example, in some embodiments thelock 520 may comprise something as simple as a removable threaded member (e.g. a bolt, a screw, and the like). In such embodiments, thelock 520 may be “opened” with a tool (e.g. a screwdriver, an Allen key, and the like) that mates with the head of the threaded member. In other embodiments, thelock 520 may be more complex, such as one requiring a key to open (e.g. a warded lock, a pin tumbler lock, a wafer tumbler lock, a disc tumbler lock or Abloy lock, a lever tumbler lock, and the like). In still other embodiments, thelock 520 may comprise a combination lock, a time lock, or any other type of lock. -
FIG. 6 illustrates another embodiment of aprotective case 600 for receiving amedical device 602 to reduce the risk of contamination of themedical device 602. Like the embodiment ofFIG. 5 , thecase 600 ofFIG. 6 includes afront portion 604 and aback portion 606, agasket 608 around the junction of the front and 604, 606, aback portions window 610 through which thedisplay 612 of themedical device 602 is visible, and atouch pad 614. An end of thecase 600 includes aport 616 through which the user may insert a plug of a USB cable. Other ports (not shown) may also be provided for connecting other cables/devices, such as a power cord. Although not shown in the drawings, in some embodiments, thecase 600 includes a separate plug that is shaped and sized to fit theport 616 and that may be used to provide themedical device 602 with a liquid tight seal when theport 616 is not in use. By establishing a liquid-tight seal through the use of the plug, thecase 600 can be cleaned and/or disinfected many times without exposing themedical device 602 to cleaning or disinfecting solutions. Although not shown in the drawings, in other embodiments thecase 600 comprises a flap that is integrally formed with the body of the case. The flap may be configured to have an unlocked and a locked position. When in the unlocked position, the flap may be opened to allow access to theport 616. Conversely, when in the locked positioned, the flap is closed and provides themedical device 600 with a liquid tight seal. In still other embodiments, closures comprising adhesives may be used to seal off theport 616 when it is not in use. - Each corner of the
case 600 includes a threadedopening 618 for receiving a fastening member, such as ascrew 620. Thescrews 620 are received in the threadedopenings 618 that extend through thefront portion 604 and at least partially through theback portion 606 to secure the front and 604, 606 to one another. In some embodiments, the opening through theback portions front portion 604 may not be threaded. Also, other fastening members, such as may be used instead of thescrews 620. - The
screws 620 provide a deterrent that discourages the patient from opening thecase 600. A head of eachscrew 620 may include a standard feature that can be engaged by one or more common tools, such as a hex key or a screwdriver (flathead or Phillips-head). Alternatively, the head of eachscrew 620 may be configured such that it will only mate with a special tool that may not be readily available to the patient. In either case, the presence of thescrews 620 provides a visual reminder to the patient that it is undesirable for him or her to open thecase 600, thereby helping to prevent contamination of themedical device 602. - The illustrated shapes and configurations of the
500, 600 ofcases FIGS. 5 and 6 are merely examples that are tailored to receive 502, 602 having the illustrated shapes, configurations, features, etc. For other medical devices having different shapes, configurations, features, etc., a given case according to the present embodiments would be shaped and configured differently than as illustrated inmedical devices FIGS. 5 and 6 in order to accommodate such other medical devices. Such changes in shape, configuration, etc. are within the scope of the present embodiments. - As discussed above, the
500, 600 described above with reference tocases FIGS. 5 and 6 restrict access to the medical device. They also cover the medical device and allow the exterior of the case to be cleaned and disinfected without damaging the functionality of the medical device. Once attached to the medical device, the case makes the unit water resistant and resistant to common cleaning and disinfection solutions and brushes. Without the case, the unit may be prone to electronics damage from liquid ingress. Further, without the case, the medical device may be prone to being scratched, dented, cracked, etc. - In some embodiments, the
500, 600 described above are resistant to common cleaning and disinfecting solutions, such as, for example, water, TERGAZYME®, bleach (e.g. up to 50% concentration), isopropyl alcohol, (ISA), etc. The protective cases are preferably made of a durable, impact-resistant plastic, and fit to the contours of the medical device. Once attached to the medical device, the cases cannot be easily removed without a tool. This feature makes the cases a semi-permanent attachment to the medical device and deters the user from removing the medical device from the cases. The protective cases have one or more access ports that allow the user to easily access any ports on the medical device. Any ports in the cases are preferably closable or coverable to enhance the water resistance of the cases. The protective cases may be used multiple times by multiple patients. The cases are preferably cleaned and disinfected between patients.protective cases - The
500, 600 described above are preferably designed to be effectively cleaned and disinfected. The following features allow the cases to be effectively cleaned and disinfected: As few grooves as possible, any grooves present are large enough to clean with wipes, as few nooks and crannies as possible, an optional antimicrobial coating, water resistance so that it can be submerged in common cleaning and disinfection solutions, resistant to cleaning brushes, able to be cleaned with moistened wipes (i.e. no brush required), and able to withstand 100 wipes with 10% bleach solution and 100 wipes with 70% isopropyl alcohol.protective cases - The
500, 600 described above preferably provide the following characteristics: Ingress Protection Rating of IPX6 or greater, full device functionality inside case (e.g. does not attenuate sound substantially, maintains access to charge port, no impact on RF performance, no impact on IEC 60601 certification of the medical device, etc.), scratch resistance, fog resistance, reduced bulkiness, little to no impact on shipping configuration/validation, and semi-permanent attachment (e.g. can only be removed with a special tool).protective cases - The protective cases described above allow the medical device to be used for multiple patients. The protective case is preferably durable so that it may be used multiple times by multiple patients, preferably being cleaned and disinfected between patients. The protective cases also preferably protect the medical device from liquid ingress, and preferably protect the medical device from common cleaning and disinfecting solutions. The protective cases also prevent the medical device from getting scratched or damaged during normal use.
- While the description above refers to a receiver of a CGM system (illustrated in
FIG. 3A ), the present embodiments are not limited to a receiver. The present embodiments are equally adaptable for use with any medical device, such as, for example, a transmitter of a CGM system, any other component of an analyte monitoring system, or any other medical device. - Certain of the present embodiments comprise methods for cleaning and disinfecting a medical device. Generally, cleaning the device involves removing soil from the device and preparing the device for disinfection. In certain embodiments, cleaning the medical device reduces protein concentration on surfaces of the medical device to less than about 6.4 μg/cm2, and reduces hemoglobin concentration on surfaces of the medical device to less than about 2.2 μg/cm2. Disinfection involves inactivating microbial organisms and/or viruses on the device, rendering the device safe for use by another patient. In certain embodiments, disinfecting the medical device achieves the following reductions in the concentration of various microbes on surfaces of the electronic device, as compared to a pre-disinfected state: duck hepatitis B virus greater than about 3 log10 reduction, klebsiella pneumonia greater than about 6 log10 reduction, staphylococcus aureus greater than about 6 log10 reduction, escherichia coli greater than about 6 log10 reduction, pseudomonas aeruginosa greater than about 6 log10 reduction, and mycobacterium terrae greater than about 3 log10 reduction.
- With reference to
FIG. 7 , one method for cleaning a medical device comprises the following steps. In box B700, an operator prepares a cleaning solution by mixing a detergent with potable tap water. For example, the detergent may comprise an enzymatic detergent containing one or more of sodium bicarbonate, sodium tripolyphosphate, sodium carbonate, sodium alkybenzene sulfonate, and other non-hazardous ingredients of less than 1% concentration. For example, the detergent may comprise TERGAZYME®, and the cleaning solution may comprise a 1% TERGAZYME® solution. The 1% TERGAZYME® solution may be produced by, for example, mixing 1¼ TBSP TERGAZYME® with ½ gallon of potable tap water. - In box B702, the operator applies clean gloves to his or her hands. The gloves are preferably resistant to chemicals that may be used in the cleaning method. In box B704, if the medical device includes any ports, such as a charging port, a USB (Universal Serial Bus) port, etc., the operator ensures that such ports are covered. For example, the medical device may include a cover for each port, such as a sliding or swinging door. If the medical device does not include a cover or covers, the operator may cover each port with a temporary, single-use, disposable port cover, which is used to protect the medical device during cleaning and disinfection (e.g. a custom or off-the-shelf plug, tape, and the like).
- In box B706, the operator moistens a clean, dry wipe or cloth with the cleaning solution and squeezes out any excess liquid. Preferably, the wipe or cloth is also low lint. For example, the wipe or cloth may comprise a microfiber wipe or cloth. In box B708, the operator wipes all surfaces of the medical device with the moistened wipe or cloth to apply cleaning solution to all surfaces. In one embodiment, a method of wiping the medical device may comprise the following steps, in no particular order: folding the wipe into quarters; with a first surface of the wipe, wiping the top of the medical device; refolding the wipe to expose a clean second surface; with the clean second surface wiping all sides of the medical device, refolding the wipe again to expose a clean third surface; and, with the clean third side of the wipe, wiping the bottom of the medical device.
- In box B710, the operator dips a brush into the cleaning solution and taps or shakes off any excess liquid. In certain embodiments, the bristles of the brush may be a soft material (e.g. nylon and the like) that will not scratch or haze the surfaces of the medical device. In box B712, the operator scrubs all surfaces of the medical device using the brush. In one embodiment, the operator may scrub the medical device for a minimum duration, such as 15 seconds, 30 seconds, 45 seconds, 60 seconds, etc. Preferably, the operator thoroughly scrubs areas where soil may collect, such as seams and crevices, e.g. around any buttons and/or ports.
- In box B714, the operator repeats boxes B706 and B708. In box B716, the operator applies a new pair of clean gloves to his or her hands. In box B720, the operator moistens a new clean, dry wipe or cloth with potable tap water and squeezes out any excess liquid. The operator then wipes all surfaces of the medical device with the moistened wipe. In one embodiment, a method of wiping the medical device may comprise the same steps outlined above with respect to box B708. In box B722, the operator dries the medical device by wiping with a clean, dry wipe or cloth, which is also preferably low-lint. The operator may refold the wipe to expose a dry surface as needed. In box B724, the operator allows the medical device to dry. In certain embodiments, the medical device may be inverted (keypad and screen facing down) for drying, and any ports thereon may remain open. In one embodiment, the operator may allow the medical device to dry for a minimum duration, such as 30 minutes, 45 minutes, 60 minutes, etc.
- With reference to
FIG. 8 , another method for cleaning a medical device comprises the following steps. In box B800, the operator prepares a cleaning solution. In certain embodiments, the cleaning solution may be prepared according to the ratios/methods described above with respect to box B700. In box B802, the operator applies a pair of clean gloves to his or her hands. In box B804, if the medical device includes any ports, such as a charging port, a USB (Universal Serial Bus) port, etc., the operator ensures that such ports are covered, similar to box B704 described above. In box B806, the operator submerges the medical device in the cleaning solution and scrubs all surfaces using a brush while the medical device is submerged. The brush and duration of scrubbing may be similar to those described above with respect to boxes B710 and B712. After brushing, the operator leaves the medical device submerged to soak in the cleaning solution for a minimum duration, such as 30 seconds, 45 seconds, 60 seconds, 90 seconds, 2 minutes, etc. In one embodiment, the total duration for which the medical device remains submerged, including scrubbing and soaking, is 3 minutes. In box B808, the operator applies a new pair of clean gloves to his or her hands. In box B810, the operator removes the medical device from the cleaning solution and rinses under running, potable tap water for a minimum duration, such as 5 seconds, 10 seconds, 15 seconds, 20 seconds, 25 seconds, 30 seconds, etc. In box B812, the operator dries the medical device by wiping with a clean, dry wipe or cloth, which is also preferably low-lint. The operator may refold the wipe to expose a dry surface as needed. - Generally, disinfecting the device involves inactivating bacteria, fungi, and/or viruses that may be resident on the medical device. In certain embodiments, the disinfecting methods include a disinfecting solution, which may be, for example, an off-the-shelf spray preparation, which may contain bleach. One such disinfecting solution may be Dispatch® Hospital Cleaner Disinfectant with Bleach, which advantageously has a short contact time and provides for ease of use. In certain embodiments, the disinfecting solution may be contained in an easy-to-use spray bottle.
- With reference to
FIG. 9 , one method for disinfecting a medical device comprises the following steps. In box B900, the operator applies a pair of clean gloves to his or her hands. In box B902, if the medical device includes any ports, such as a charging port, a USB (Universal Serial Bus) port, etc., the operator ensures that such ports are covered, similar to box B704 described above. In box B904, the operator places the medical device screen side (front side) up on a clean, flat surface. In box B906, the operator holds the disinfecting solution spray bottle proximate the medical device front surface. For example, in one embodiment the operator may hold the spray bottle 6″-8″ from the medical device front surface. In box B908, the operator sprays the disinfecting solution onto the medical device front surface until thoroughly wetted. The operator may tilt the medical device if necessary to ensure the disinfecting solution has covered the entire front surface. In box B910, the operator turns the medical device over so that the back surface is facing up. In box B912, the operator wets the medical device back surface with the disinfecting solution in the same manner as in boxes B906 and B908. - In box B914, the operator wets each side (or edge) of the medical device with the disinfecting solution in the same manner as in boxes B906 and B908. However, in certain embodiments, the operator does not wet (or at least does not directly spray) any side of the medical device that includes at least one port. In box B916, the operator allows the medical device to sit wetted for a minimum duration, such as 30 seconds, 45 seconds, 60 seconds, 90 seconds, 2 minutes, 5 minutes, etc.
- In box B918, the operator wets an absorbent wipe with a second disinfecting solution, such as a 70% isopropyl alcohol (IPA) solution. In box B920, the operator wipes down all outside surfaces of the medical device to remove any residue, such as bleach residue. In box B922, the operator uncovers any ports that were covered in box B902 and wipes or dabs any liquid residue from interior surfaces of the port(s). Preferably, the operator avoids contacting any metal components of the port(s) with the second disinfecting solution so as to avoid causing an electrical short.
- In box B924, the operator wipes the exterior of the medical device completely dry with an absorbent wipe, and dries around any ports with an absorbent wipe if any liquid is observed. In box B926, the operator allows the medical device to dry in the same manner as described with respect to box B724.
- With reference to
FIG. 10 , another method for disinfecting a medical device comprises the following steps. In box B1000, the operator applies a pair of clean gloves to his or her hands. In box B1002, the operator places the medical device on a flat surface such that any electrical contacts thereon face the flat surface. In boxes B1004 and B1006, the operator wets the medical device front surface with the disinfecting solution in a similar manner as described above with respect to boxes B906 and B908. In box B1008, the operator turns the medical device over so that the electrical contacts face up. In box B1010, the operator wets the medical device back surface with the disinfecting solution in the same manner as in boxes B1004 and B1006. - In box B1012, the operator allows the medical device to sit wetted for a minimum duration, such as 30 seconds, 45 seconds, 60 seconds, 90 seconds, 2 minutes, 5 minutes, etc. In box B1014, the operator wipes the medical device completely dry with an absorbent wipe. In box B1016, the operator wets an absorbent wipe with a second disinfecting solution, such as a 70% isopropyl alcohol (IPA) solution. In box B1018, the operator wipes down all outside surfaces of the medical device to remove any residue, such as bleach residue. In box B1020, the operator allows the medical device to dry in the same manner as described with respect to box B724.
- With reference to
FIG. 11 , another method for cleaning a medical device comprises the following steps. In box B1100, the operator applies a pair of clean gloves to his or her hands. In box B1102, the operator prepares a soaking solution by adding enough bleach solution to a container to submerge the medical device. In box B1104, the operator places the medical device on a flat surface such that any electrical contacts thereon face the flat surface. In boxes B1106 and B1108, the operator wets the medical device front surface with the disinfecting solution in a similar manner as described above with respect to boxes B906 and B908. In box B1110, the operator turns the medical device over so that the electrical contacts face up. In box B1112, the operator wets the medical device back surface with the disinfecting solution in the same manner as in boxes B1104 and B1106. - In box B1114, the operator scrubs all surfaces of the medical device using a brush for a minimum duration. In box B1116, the operator submerges the medical device in the cleaning solution for a minimum duration. In box B1118, the operator removes the medical device from the cleaning solution and rinses it under tap water for a minimum duration. In box B1120, the operator wipes the medical device completely dry.
- With reference to
FIG. 12 , another method for disinfecting a medical device comprises the following steps. In box B1200, the operator applies a pair of clean gloves to his or her hands and goggles over his or her eyes. In box B1202, the operator prepares a soaking solution by adding enough bleach solution to a container to submerge the medical device. In box B1204, the operator removes a pre-saturated disinfectant (e.g. bleach) wipe from its packaging. In box B1206, the operator folds the wipe into a 2″×2″ square. In box B1208, the operator wipes all surfaces of the medical device by passing over the medical device surface in one direction and then hack in the opposite direction (hack and forth, two passes). In box B1210, the operator turns over the wipe to use a clean side for a second back and forth wipe. In box B1212, the operator refolds the wipe to use a clean side for a third back and forth wipe. In box B1214, the operator turns over the wipe to use a clean side for a fourth back and forth wipe for a total of eight passes, ensuring that all medical device surfaces are covered with disinfectant (e.g. bleach). - In box B1216, the operator places the medical device on a clean, non-porous surface and allows the disinfectant to contact the medical device for a minimum duration. In box B1218, the operator places the medical device in the soaking solution for a minimum duration. In box B1220, the operator removes the medical device from the soaking solution and rinses it under flowing tap water for a minimum duration. In box B1222, the operator wipes the medical device with a cloth until it is completely dry.
- In a further embodiment, an electronic medical device, such as the electronic
medical device 201 shown inFIG. 3A , may include a coating of a liquid repellant (e.g., hydrophobic) substance. The coating may surround all exposed electrical surfaces of the electronic medical device and seal any cracks, fissures, etc. The coating may be invisible to the human eye. For example, one suitable coating is available from Liquipel of Santa Ana, Calif. In one study, tests were conducted comparing the effectiveness of the above-described coating in allowing a medical device to be cleaned and in a variety of cleaning solutions without sustaining damage. In this study, five DexCom G4® Platinum receivers comprising the test group were coated with Liquipel. Another five DexCom G4® Platinum receivers comprising the control group were not coated with Liquipel. The study comprised 10 cleaning cycles, in which each cleaning cycle comprised the following steps: (1) wiping the receiver with a detergent; (2) brushing the receiver while exposed to the detergent; (3) wiping the receiver with the detergent; (4) wiping the receiver with water; (5) wiping dry the receiver; (6) setting the receiver for five minutes; (7) spraying the receiver with bleach; (8) setting the receiver for five minutes; (9) wiping dry the receiver; (10) wiping the receiver with alcohol; (11) wiping dry the receiver; (12) setting the receiver for one hour. With the test group, all five receivers underwent the 10 cleaning cycles without suffering any failures. With the control, however, only one of the four receivers did not suffer failure after the 10 cleaning cycles. Of the five receivers in the control group, two suffered USB failure by the fourth cleaning cycle, one suffered USB failure by the eighth cleaning cycle, and one suffered an unintended reset (i.e., stuck in manufacturing mode) by the second cleaning cycle. The study clearly demonstrated the viability of coating a medical device with a liquid repellant substance (e.g., Liquipel) to transform it into a device that can be exposed to common cleaning agents, such as detergent, bleach, and/or water, without sustaining damage. - As expected, positive control receivers exhibited failures due to liquid ingress.
- a. 80% failure rate after 10 cycles of cleaning and disinfection.
- As expected, negative control receivers continued to function properly due to no liquid exposure.
- a. 0% failure rate.
- Liquipel was effective at protecting the receiver from damage due to liquid ingress.
-
- a. All Liquipel receivers continued to function properly after 10 cycles of cleaning and disinfection.
- b. 0% failure rate after 10 cycles of cleaning and disinfection
In an example process of applying the coating to the electronic medical device, the device placed in an airtight chamber from which substantially all air is evacuated to create a vacuum. Once the vacuum has been established, the coating material may be injected into the chamber in liquid form. Upon entering the vacuum chamber, the liquid becomes a gas. Plasma is then introduced into the vacuum chamber. The plasma decomposes the liquid repellant molecules, polymerizing them to themselves. Air is then reintroduced into the chamber until it returns to atmospheric pressure. The electronic medical device is then removed from the chamber and the process is complete.
- The above description presents the best mode contemplated for carrying out the present invention, and of the manner and process of practicing it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which they pertain to practice this invention. This invention is, however, susceptible to modifications and alternate constructions from those discussed above that are fully equivalent. Consequently, this invention is not limited to the particular embodiments disclosed. On the contrary, this invention covers all modifications and alternate constructions coming within the spirit and scope of the invention as generally expressed by the following claims, which particularly point out and distinctly claim the subject matter of the invention.
- While various embodiments of the invention have been described above, it should be understood that they have been presented by way of example only, and not by way of limitation. Likewise, the various diagrams may depict an example architectural or other configuration for the disclosure, which is done to aid in understanding the features and functionality that can be included in the disclosure. The disclosure is not restricted to the illustrated example architectures or configurations, but can be implemented using a variety of alternative architectures and configurations. Additionally, although the disclosure is described above in terms of various exemplary embodiments and implementations, it should be understood that the various features and functionality described in one or more of the individual embodiments are not limited in their applicability to the particular embodiment with which they are described. They instead can be applied, alone or in some combination, to one or more of the other embodiments of the disclosure, whether or not such embodiments are described, and whether or not such features are presented as being a part of a described embodiment. Thus the breadth and scope of the present disclosure should not be limited by any of the above-described exemplary embodiments.
- It will be appreciated that, for clarity purposes, the above description has described embodiments with reference to different functional units. However, it will be apparent that any suitable distribution of functionality between different functional units may be used without detracting from the invention. For example, functionality illustrated to be performed by separate computing devices may be performed by the same computing device. Likewise, functionality illustrated to be performed by a single computing device may be distributed amongst several computing devices. Hence, references to specific functional units are only to be seen as references to suitable means for providing the described functionality, rather than indicative of a strict logical or physical structure or organization.
- Embodiments of the present disclosure are described above and below with reference to flowchart illustrations of methods, apparatus, and computer program products. It will be understood that each block of the flowchart illustrations, and combinations of blocks in the flowchart illustrations, can be implemented by execution of computer program instructions. These computer program instructions may be loaded onto a computer or other programmable data processing apparatus (such as a controller, microcontroller, microprocessor or the like) in a sensor electronics system to produce a machine, such that the instructions which execute on the computer or other programmable data processing apparatus create instructions for implementing the functions specified in the flowchart block or blocks. These computer program instructions may also be stored in a computer-readable memory that can direct a computer or other programmable data processing apparatus to function in a particular manner, such that the instructions stored in the computer-readable memory produce an article of manufacture including instructions which implement the function specified in the flowchart block or blocks. The computer program instructions may also be loaded onto a computer or other programmable data processing apparatus to cause a series of operational steps to be performed on the computer or other programmable apparatus to produce a computer implemented process such that the instructions which execute on the computer or other programmable apparatus provide steps for implementing the functions specified in the flowchart block or blocks presented herein.
- It should be appreciated that all methods and processes disclosed herein may be used in any glucose monitoring system, continuous or intermittent. It should further be appreciated that the implementation and/or execution of all methods and processes may be performed by any suitable devices or systems, whether local or remote. Further, any combination of devices or systems may be used to implement the present methods and processes.
- While the disclosure has been illustrated and described in detail in the drawings and foregoing description, such illustration and description are to be considered illustrative or exemplary and not restrictive. The disclosure is not limited to the disclosed embodiments. Variations to the disclosed embodiments can be understood and effected by those skilled in the art in practicing the claimed disclosure, from a study of the drawings, the disclosure and the appended claims.
- All references cited herein are incorporated herein by reference in their entirety. To the extent publications and patents or patent applications incorporated by reference contradict the disclosure contained in the specification, the specification is intended to supersede and/or take precedence over any such contradictory material.
- Unless otherwise defined, all terms (including technical and scientific terms) are to be given their ordinary and customary meaning to a person of ordinary skill in the art, and are not to be limited to a special or customized meaning unless expressly so defined herein. It should be noted that the use of particular terminology when describing certain features or aspects of the disclosure should not be taken to imply that the terminology is being re-defined herein to be restricted to include any specific characteristics of the features or aspects of the disclosure with which that terminology is associated. Terms and phrases used in this application, and variations thereof, especially in the appended claims, unless otherwise expressly stated, should be construed as open ended as opposed to limiting. As examples of the foregoing, the term ‘including’ should be read to mean ‘including, without limitation,’ ‘including but not limited to,’ or the like; the term ‘comprising’ as used herein is synonymous with ‘including,’ ‘containing,’ or ‘characterized by,’ and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps; the term ‘having’ should be interpreted as ‘having at least;’ the term ‘includes’ should be interpreted as ‘includes but is not limited to;’ the term ‘example’ is used to provide exemplary instances of the item in discussion, not an exhaustive or limiting list thereof; adjectives such as ‘known’, ‘normal’, ‘standard’, and terms of similar meaning should not be construed as limiting the item described to a given time period or to an item available as of a given time, but instead should be read to encompass known, normal, or standard technologies that may be available or known now or at any time in the future; and use of terms like ‘preferably,’ ‘preferred,’ ‘desired,’ or ‘desirable,’ and words of similar meaning should not be understood as implying that certain features are critical, essential, or even important to the structure or function of the invention, but instead as merely intended to highlight alternative or additional features that may or may not be utilized in a particular embodiment of the invention. Likewise, a group of items linked with the conjunction ‘and’ should not be read as requiring that each and every one of those items be present in the grouping, but rather should be read as ‘and/or’ unless expressly stated otherwise. Similarly, a group of items linked with the conjunction ‘or’ should not be read as requiring mutual exclusivity among that group, but rather should be read as ‘and/or’ unless expressly stated otherwise.
- Where a range of values is provided, it is understood that the upper and lower limit, and each intervening value between the upper and lower limit of the range is encompassed within the embodiments.
- With respect to the use of substantially any plural and/or singular terms herein, those having skill in the art can translate from the plural to the singular and/or from the singular to the plural as is appropriate to the context and/or application. The various singular/plural permutations may be expressly set forth herein for sake of clarity. The indefinite article “a” or “an” does not exclude a plurality. A single processor or other unit may fulfill the functions of several items recited in the claims. The mere fact that certain measures are recited in mutually different dependent claims does not indicate that a combination of these measures cannot be used to advantage. Any reference signs in the claims should not be construed as limiting the scope.
- It will be further understood by those within the art that if a specific number of an introduced claim recitation is intended, such an intent will be explicitly recited in the claim, and in the absence of such recitation no such intent is present. For example, as an aid to understanding, the following appended claims may contain usage of the introductory phrases “at least one” and “one or more” to introduce claim recitations. However, the use of such phrases should not be construed to imply that the introduction of a claim recitation by the indefinite articles “a” or “an” limits any particular claim containing such introduced claim recitation to embodiments containing only one such recitation, even when the same claim includes the introductory phrases “one or more” or “at least one” and indefinite articles such as “a” or “an” (e.g., “a” and/or “an” should typically be interpreted to mean “at least one” or “one or more”); the same holds true for the use of definite articles used to introduce claim recitations. In addition, even if a specific number of an introduced claim recitation is explicitly recited, those skilled in the art will recognize that such recitation should typically be interpreted to mean at least the recited number (e.g., the bare recitation of “two recitations,” without other modifiers, typically means at least two recitations, or two or more recitations). Furthermore, in those instances where a convention analogous to “at least one of A, B, and C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, and C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). In those instances where a convention analogous to “at least one of A, B, or C, etc.” is used, in general such a construction is intended in the sense one having skill in the art would understand the convention (e.g., “a system having at least one of A, B, or C” would include but not be limited to systems that have A alone, B alone, C alone, A and B together, A and C together, B and C together, and/or A, B, and C together, etc.). It will be further understood by those within the art that virtually any disjunctive word and/or phrase presenting two or more alternative terms, whether in the description, claims, or drawings, should be understood to contemplate the possibilities of including one of the terms, either of the terms, or both terms. For example, the phrase “A or B” will be understood to include the possibilities of “A” or “B” or “A and B.”
- All numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification are to be understood as being modified in all instances by the term ‘about.’ Accordingly, unless indicated to the contrary, the numerical parameters set forth herein are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of any claims in any application claiming priority to the present application, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
Claims (20)
1. An enclosure for an electronic medical device, the enclosure comprising:
a sleeve configured to receive an electronic medical device having a port;
a first opening in the sleeve sized and configured to allow for insertion of the electronic medical device into the sleeve and removal of the electronic medical device from the sleeve;
a second opening in the sleeve, the second opening being located so as to permit access to the port when the electronic medical device is received within the sleeve;
a first cover configured to adhere to a first portion of the sleeve and to cover the first opening; and
a second cover configured to adhere to a second portion of the sleeve and to cover the second opening.
2. The enclosure of claim 1 , further comprising a first adhesive located and configured to secure the first cover to the sleeve at the first portion.
3. The enclosure of claim 2 , further comprising a second adhesive located and configured to secure the second cover to the sleeve at the second portion.
4. The enclosure of claim 3 , wherein the first adhesive comprises a first peel strength, the second adhesive comprises a second peel strength, and the first peel strength is different than the second peel strength.
5. The enclosure of claim 4 , wherein the first peel strength is greater than the second peel strength.
6. The enclosure of claim 4 , wherein the first peel strength is great enough to prevent separation of the first cover from the sleeve without tearing the sleeve.
7. The enclosure of claim 1 , wherein the port is at least one of a charging port or a communication port.
8. The enclosure of claim 7 , wherein the communication port is a USB port.
9. The enclosure of claim 1 , wherein the sleeve comprises a material selected from the group consisting of polyurethane, polyethylene, and low density polyethylene.
10. The enclosure of claim 1 , wherein the sleeve comprises a first portion comprising a first material and a second portion comprising a second material.
11. The enclosure of claim 10 , wherein the second material has greater stiffness than the first material.
12. The enclosure of claim 10 , wherein the first portion comprises a material selected from the group consisting of polyurethane, polyethylene, and low density polyethylene.
13. The enclosure of claim 10 , wherein the second portion comprises a material selected from the group consisting of polycarbonate and acrylonitrile butadiene styrene.
14. The enclosure of claim 10 , wherein the second portion is configured to provide access to the port.
15. The enclosure of claim 10 , wherein the first opening is surrounded by the first portion, and wherein the second opening is surrounded by the second portion.
16. The enclosure of claim 1 , wherein the first opening comprises a first slit that extends in a longitudinal direction, and a second slit that extends in a transverse direction.
17. The enclosure of claim 16 , wherein a first end of the first slit corresponds to a lengthwise center of the second slit.
18. The enclosure of claim 16 , wherein the electronic medical device is configured to display continuous glucose concentration data over a time period.
19. A method for reprocessing a reusable electronic medical device, the method comprising:
receiving an electronic medical device from a first user, wherein the electronic medical device is contained in a first protective enclosure;
removing the electronic medical device from the first protective enclosure;
inserting the electronic medical device into a second protective enclosure through an opening in the second protective enclosure;
adhering a cover to the second protective enclosure over the opening; and
providing the electronic medical device contained within the second protective enclosure to a second user.
20. The method of claim 19 , further comprising creating a disinfected field, wherein removing the electronic medical device from the first protective enclosure and placing the electronic medical device in a second protective enclosure are performed in the disinfected field.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16/360,295 US20190216375A1 (en) | 2013-10-21 | 2019-03-21 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
| US17/451,474 US11872036B2 (en) | 2013-10-21 | 2021-10-19 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
| US18/531,599 US20240099613A1 (en) | 2013-10-21 | 2023-12-06 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361893822P | 2013-10-21 | 2013-10-21 | |
| US14/505,451 US9375065B2 (en) | 2013-10-21 | 2014-10-02 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
| US15/194,242 US9962114B2 (en) | 2013-10-21 | 2016-06-27 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
| US15/934,008 US10278623B2 (en) | 2013-10-21 | 2018-03-23 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
| US16/360,295 US20190216375A1 (en) | 2013-10-21 | 2019-03-21 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/934,008 Continuation US10278623B2 (en) | 2013-10-21 | 2018-03-23 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/451,474 Continuation US11872036B2 (en) | 2013-10-21 | 2021-10-19 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20190216375A1 true US20190216375A1 (en) | 2019-07-18 |
Family
ID=52825283
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/505,451 Active US9375065B2 (en) | 2013-10-21 | 2014-10-02 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
| US15/194,242 Active US9962114B2 (en) | 2013-10-21 | 2016-06-27 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
| US15/934,008 Active US10278623B2 (en) | 2013-10-21 | 2018-03-23 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
| US16/360,295 Abandoned US20190216375A1 (en) | 2013-10-21 | 2019-03-21 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
| US17/451,474 Active 2034-10-12 US11872036B2 (en) | 2013-10-21 | 2021-10-19 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
| US18/531,599 Pending US20240099613A1 (en) | 2013-10-21 | 2023-12-06 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/505,451 Active US9375065B2 (en) | 2013-10-21 | 2014-10-02 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
| US15/194,242 Active US9962114B2 (en) | 2013-10-21 | 2016-06-27 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
| US15/934,008 Active US10278623B2 (en) | 2013-10-21 | 2018-03-23 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US17/451,474 Active 2034-10-12 US11872036B2 (en) | 2013-10-21 | 2021-10-19 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
| US18/531,599 Pending US20240099613A1 (en) | 2013-10-21 | 2023-12-06 | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
Country Status (1)
| Country | Link |
|---|---|
| US (6) | US9375065B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11872036B2 (en) | 2013-10-21 | 2024-01-16 | Dexcom, Inc. | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150305480A1 (en) * | 2014-03-20 | 2015-10-29 | Jean-Philippe Brousseau | Loop suitable for use with a variety of objects |
| CN110072408B (en) * | 2016-04-22 | 2021-07-16 | 奈爱股份有限公司 | Mobile device connection device |
| US10307803B2 (en) | 2016-07-20 | 2019-06-04 | The United States Of America As Represented By Secretary Of The Navy | Transmission window cleanliness for directed energy devices |
| US20230320468A1 (en) * | 2022-04-08 | 2023-10-12 | Janet Cochran | Touch Sensitive and Transparent Protective Cover for Handheld Electronic Devices |
| US12411527B1 (en) * | 2022-08-11 | 2025-09-09 | Wynnshield Llc | Wrap for handheld electronic device and methods for using same |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5454896A (en) * | 1994-07-07 | 1995-10-03 | The Procter & Gamble Company | Method for attaching a flexible inner bag to the inside of a squeezebottle |
| US5584409A (en) * | 1995-09-18 | 1996-12-17 | Chemberlen; Christopher H. | One direction ventilation valves |
| US20030021729A1 (en) * | 2001-07-26 | 2003-01-30 | Bayer Corporation | Removable cover for a glucose meter |
| US7609512B2 (en) | 2001-11-19 | 2009-10-27 | Otter Products, Llc | Protective enclosure for electronic device |
| US8137618B2 (en) * | 2004-08-18 | 2012-03-20 | Abbott Laboratories | Blood glucose monitoring kit |
| US20090262492A1 (en) | 2007-10-26 | 2009-10-22 | Seal Shield, Llc | Submersible keyboard |
| US20100004522A1 (en) * | 2008-07-02 | 2010-01-07 | Eddie Varela | Continuously Wearable Compact Blood Glucose Measuring Device |
| US9078498B2 (en) | 2009-09-30 | 2015-07-14 | Otter Products, Llc | Holder |
| EP2335565A1 (en) * | 2009-12-18 | 2011-06-22 | Roche Diagnostics GmbH | Protective container for holding reusable diagnostic components |
| US9089338B2 (en) * | 2010-11-05 | 2015-07-28 | Ethicon Endo-Surgery, Inc. | Medical device packaging with window for insertion of reusable component |
| US9730621B2 (en) | 2012-12-31 | 2017-08-15 | Dexcom, Inc. | Remote monitoring of analyte measurements |
| US9375065B2 (en) * | 2013-10-21 | 2016-06-28 | Dexcom, Inc. | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
-
2014
- 2014-10-02 US US14/505,451 patent/US9375065B2/en active Active
-
2016
- 2016-06-27 US US15/194,242 patent/US9962114B2/en active Active
-
2018
- 2018-03-23 US US15/934,008 patent/US10278623B2/en active Active
-
2019
- 2019-03-21 US US16/360,295 patent/US20190216375A1/en not_active Abandoned
-
2021
- 2021-10-19 US US17/451,474 patent/US11872036B2/en active Active
-
2023
- 2023-12-06 US US18/531,599 patent/US20240099613A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11872036B2 (en) | 2013-10-21 | 2024-01-16 | Dexcom, Inc. | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device |
Also Published As
| Publication number | Publication date |
|---|---|
| US10278623B2 (en) | 2019-05-07 |
| US20150108185A1 (en) | 2015-04-23 |
| US20180214056A1 (en) | 2018-08-02 |
| US11872036B2 (en) | 2024-01-16 |
| US20240099613A1 (en) | 2024-03-28 |
| US20220031207A1 (en) | 2022-02-03 |
| US20160302703A1 (en) | 2016-10-20 |
| US9375065B2 (en) | 2016-06-28 |
| US9962114B2 (en) | 2018-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11872036B2 (en) | Apparatus and methods for maintaining a medical device in a clean and disinfected state, and for cleaning and disinfecting a medical device | |
| US20250091748A1 (en) | Packaging system for analyte sensors | |
| US12144578B2 (en) | Continuous analyte monitor data recording device operable in a blinded mode | |
| EP4154802B1 (en) | Applicators for applying transcutaneous analyte sensors | |
| EP2497420B1 (en) | Processing analyte sensor data | |
| US20100185065A1 (en) | System and methods for processing analyte sensor data | |
| US20120283541A1 (en) | System and methods for processing analyte sensor data |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: DEXCOM, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:POLYTARIDIS, NICHOLAS;CARNER, DAVID J.;LEACH, JACOB S.;AND OTHERS;SIGNING DATES FROM 20141114 TO 20141202;REEL/FRAME:051454/0936 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |